<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Autism spectrum disorder in children and adolescents: Pharmacologic interventions</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Autism spectrum disorder in children and adolescents: Pharmacologic interventions</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Autism spectrum disorder in children and adolescents: Pharmacologic interventions</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laura Weissman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marilyn Augustyn, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 27, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Autism spectrum disorder (ASD) is a biologically based neurodevelopmental disorder characterized by impairments in two major domains: (1) deficits in social communication and social interaction and (2) restricted repetitive patterns of behavior, interests, and activities [<a href="#rid1">1</a>]. ASD encompasses disorders previously known as autistic disorder (classic autism, sometimes called early infantile autism, childhood autism, or Kanner's autism), childhood disintegrative disorder, pervasive developmental disorder not otherwise specified, and Asperger disorder (also known as Asperger syndrome). (See  <a class="medical medical_review" href="/d/html/628.html" rel="external">"Autism spectrum disorder in children and adolescents: Evaluation and diagnosis", section on 'Diagnostic criteria'</a>.)</p><p>The discussion that follows will focus on pharmacologic interventions for autism. Related topics are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/627.html" rel="external">"Autism spectrum disorder in children and adolescents: Clinical features"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/628.html" rel="external">"Autism spectrum disorder in children and adolescents: Evaluation and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/608.html" rel="external">"Autism spectrum disorder in children and adolescents: Overview of management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/607.html" rel="external">"Autism spectrum disorder in children and adolescents: Behavioral and educational interventions"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/605.html" rel="external">"Autism spectrum disorder in children and adolescents: Complementary and alternative therapies"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/595.html" rel="external">"Autism spectrum disorder (ASD) in children and adolescents: Terminology, epidemiology, and pathogenesis"</a>.)</p><p></p><p></p><p class="headingAnchor" id="H2"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H3"><span class="h2">Overview</span><span class="headingEndMark"> — </span>The clinical manifestations of ASD vary in intensity, and treatment plans must be individualized. The primary treatments are developmental and behavioral therapies, typically as part of Early Intervention or school-based programming. Psychopharmacologic interventions may be a useful adjunct to behavioral/environmental interventions in children with ASD after behavioral and educational supports have been maximized including supports to improve the child's comprehension and ability to communicate. (See  <a class="medical medical_review" href="/d/html/607.html" rel="external">"Autism spectrum disorder in children and adolescents: Behavioral and educational interventions"</a>.)</p><p>Psychopharmacologic agents do not treat autism itself and should be initiated only after educational and behavioral interventions are in place, comorbid psychiatric or medical illnesses ruled out, and psychosocial/environmental stressors considered [<a href="#rid2">2</a>]. In addition to a thorough medical assessment, formal behavioral analysis conducted by a behavior analyst or behavioral psychologist may be warranted to clarify the nature of the symptoms under consideration for treatment. Depending on regional systems and resources, this may be arranged through the child's educational team at school.</p><p>The potential benefits and risks of pharmacologic therapy for children with ASD must be weighed on a case-by-case basis. Parents and caregivers should be informed if the medication is being used off-label (only <a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">risperidone</a> and <a class="drug drug_pediatric" data-topicid="13180" href="/d/drug information/13180.html" rel="external">aripiprazole</a> are approved by the US Food and Drug Administration [FDA] specifically for irritability in children with ASD).</p><p>The principles for the psychopharmacologic management of individuals with ASD are the same as for individuals with other psychiatric conditions. Medications should be used to target specific symptoms that are clearly defined, and the symptoms should be measured over time (preferably using rating scales) to monitor treatment efficacy. It is also important to periodically re-evaluate the need for continued treatment.</p><p>Children with ASD are more sensitive to psychopharmacotherapy and more likely to have adverse effects than children without ASD [<a href="#rid3">3,4</a>]. In addition, given their weaknesses communicating and identifying their emotions, it can be difficult to determine the predominant target symptom (eg, anxiety, impulsivity, anger) and, therefore, the best psychopharmacologic agent. For similar reasons, it can be more challenging to monitor certain side effects of medications (eg, dry mouth, dizziness).</p><p class="headingAnchor" id="H4"><span class="h2">Pretreatment evaluation</span><span class="headingEndMark"> — </span>Medication may be warranted if the child's behavior interferes with his or her ability to access therapy and other contributing factors (eg, comorbid illness, psychosocial/environmental stressors) have been addressed. However, determining which symptoms to target with medication can be challenging. Few of the various measures for assessing behavior in children (eg, Vanderbilt scales for attention) are standardized for children with ASD [<a href="#rid5">5,6</a>]. Behavior scales must be used in conjunction with appropriate clinical and historical data. Thorough clinical assessment, including information collection from multiple sources (eg, parents, therapists), may be necessary to identify the most relevant target behavior.</p><p>If available, Functional Behavioral Assessment (FBA) by the child's behavioral therapist can provide valuable information. FBA is a formal, systematic observation that includes identifying target behaviors, antecedents, and outcomes in order to better understand the function of the behavior. Understanding the function of the behavior helps the clinician to identify an appropriate target for medication. As an example, aggression may result from impulsivity, anxiety, irritability, or other psychiatric problem (eg, mood or psychotic disorder), which are treated with different psychopharmacologic agents.</p><p>If FBA is not available, the clinician should work to identify and characterize each target behavior (with input from parents, other caregivers, and school staff, if possible) in terms of [<a href="#rid7">7-9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>How long has it been present? How severe is it?</p><p class="bulletIndent1"><span class="glyph">●</span>What brings it on or makes it worse (eg, time, setting, demands, etc)? Is it amenable to behavioral interventions?</p><p class="bulletIndent1"><span class="glyph">●</span>Are medical factors contributing (eg, dental or other pain, constipation or gastrointestinal distress, infection, sleep, seizures, menstrual cycle, etc)?</p><p class="bulletIndent1"><span class="glyph">●</span>What makes it better? How does it respond to behavioral interventions?</p><p class="bulletIndent1"><span class="glyph">●</span>What is the course? Is it getting better or worse?</p><p class="bulletIndent1"><span class="glyph">●</span>Does it interfere with function?</p><p class="bulletIndent1"><span class="glyph">●</span>What supports are available (eg, behavioral services, educational program, respite care, family support)?</p><p></p><p>If the symptoms meet criteria for a comorbid psychiatric condition (eg, depression, attention deficit hyperactivity disorder [ADHD], anxiety), the disorder should be managed accordingly, with the caveat that the response to medication may differ in children and adolescents for whom this is a secondary rather than a primary diagnosis. (See  <a class="medical medical_review" href="/d/html/1231.html" rel="external">"Overview of prevention and treatment for pediatric depression"</a> and  <a class="medical medical_review" href="/d/html/623.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis", section on 'Overview of management'</a> and  <a class="medical medical_review" href="/d/html/15928.html" rel="external">"Pharmacotherapy for anxiety disorders in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/15927.html" rel="external">"Psychotherapy for anxiety disorders in children and adolescents"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Pharmacologic therapy for children with ASD may be warranted for the treatment of comorbid psychiatric or neurodevelopmental conditions or for behavioral symptoms that interfere with learning, socialization, health, safety, quality of life, or overall functioning [<a href="#rid7">7-10</a>]. When considering the use of medications for target symptoms in children with ASD, the potential benefits and risks must be weighed on a case-by-case basis. Pharmacologic therapy generally is initiated after behavioral and environmental interventions are in place and have been maximized.</p><p class="headingAnchor" id="H6"><span class="h2">Who should prescribe?</span><span class="headingEndMark"> — </span>Psychopharmacotherapy for children and adolescents with ASD ideally is prescribed by specialists familiar with ASD (eg, developmental-behavioral pediatricians, child psychiatrists, child neurologists, etc). However, access to such specialists is not always available. If primary care clinicians undertake the prescription of psychotropic agents for children with ASD, consultation with a developmental-behavioral pediatrician, child psychiatrist, child neurologist, or another mental health professional who is familiar with ASD may be warranted to ensure that an appropriate medication is chosen and efficacy and adverse effects are appropriately monitored.</p><p class="headingAnchor" id="H7"><span class="h2">Choice of agent</span><span class="headingEndMark"> — </span>Factors to consider in choosing pharmacologic therapy for children with ASD include  (<a class="graphic graphic_table graphicRef80456" href="/d/graphic/80456.html" rel="external">table 1</a>) [<a href="#rid7">7,9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Likelihood of improvement in the target symptom</p><p class="bulletIndent1"><span class="glyph">●</span>Potential adverse effects</p><p class="bulletIndent1"><span class="glyph">●</span>Practical considerations (available formulations, dosing schedule, cost, requirement for laboratory monitoring)</p><p></p><p><a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">Risperidone</a> and <a class="drug drug_pediatric" data-topicid="13180" href="/d/drug information/13180.html" rel="external">aripiprazole</a> are the only psychotropic medications approved by the FDA specifically for treatment of individuals with ASD [<a href="#rid11">11</a>]. However, many other medications are used off-label. Parents and caregivers should be informed if the medication is being used off-label.</p><p>The study of psychopharmacologic interventions in children with ASD is ongoing [<a href="#rid12">12,13</a>]. Most of the existing evidence is extrapolated from studies on comorbid conditions (eg, ADHD, obsessive compulsive disorder, anxiety, etc) in children without ASD. Studies of pharmacotherapy in children with ASD generally are small, retrospective, and nonblinded; they are hampered by the lack of diagnostic tools that have been standardized in the ASD population. Notable exceptions include <a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">risperidone</a> and <a class="drug drug_pediatric" data-topicid="13180" href="/d/drug information/13180.html" rel="external">aripiprazole</a> for the treatment of disruptive behaviors and <a class="drug drug_pediatric" data-topicid="12600" href="/d/drug information/12600.html" rel="external">methylphenidate</a> for the treatment of disruptive behaviors and hyperactivity/inattention [<a href="#rid14">14,15</a>]. (See <a class="local">'Risperidone'</a> below and <a class="local">'Aripiprazole'</a> below and <a class="local">'Stimulants'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Children with ASD are more sensitive to medication effects and more likely to have adverse effects than children without ASD [<a href="#rid3">3,4</a>]. Medications should be started at lower doses, and doses should be increased more slowly than in patients without ASD.</p><p>The efficacy and adverse effects of pharmacologic agents should be monitored systematically during therapy [<a href="#rid7">7,9</a>]. In addition to clinical history, an appropriate tool should be used to monitor outcome if such a tool is available. Target symptoms of children receiving intensive behavioral interventions can be monitored using standardized instruments for specific symptoms (eg, attention rating scales) although these instruments have not been validated for use in individuals with ASD. In addition, many children with ASD have structured behavioral programming as a component of their educational and therapeutic program. The data collection techniques included in their behavioral programming can also be used for monitoring response to medications. For children who do not have this type of programming, the prescribing clinician can work with the child's family and school staff to develop of system for monitoring target symptoms and providing feedback about response to medications. (See  <a class="medical medical_review" href="/d/html/607.html" rel="external">"Autism spectrum disorder in children and adolescents: Behavioral and educational interventions", section on 'Intensive behavioral interventions'</a>.)</p><p>Autism Speaks provides a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.autismspeaks.org%2Ftool-kit%2Fatnair-p-autism-and-medication-safe-and-careful-use&amp;token=FgRqMjuFLc1bWA8FBE8frK7l%2B12mVXavvgTFyT3mK%2FTpZl2SCcBhNUcUX%2FWySI95O2Q931%2Bi0qqhaSBcKvIKu8bXi6OA89U3us8P6MAr%2FQk%3D&amp;TOPIC_ID=603" target="_blank">toolkit</a> to help families and providers ensure safe and careful use of medications.</p><p>The schedule for follow-up should permit an adequate trial of therapy, as well as a timely modification (different dose, different medication, discontinuation) if the desired effect does not occur. The specific follow-up interval varies with the medication but generally should be no longer than three months. After successful control of the target symptom for 6 to 12 months, withdrawal of the medication for a period of time may be warranted to determine whether it is still necessary.</p><p>The parents and caregivers should be provided with information about the prescribed medication and its potential adverse effects.</p><p class="headingAnchor" id="H591288613"><span class="h2">Polypharmacy</span><span class="headingEndMark"> — </span>It is important to consider additional precautions when prescribing more than one psychoactive medication for patients with ASD. Many medications used for treating maladaptive behavior or mood symptoms have sedative effects and taking more than one may result in excessive daytime sedation. In addition, some medications that share a metabolic pathway may either enhance or inhibit the metabolism of other drugs, requiring dosing adjustments. Finally, several medications can prolong QTc and may have additive effects on heart conduction when used simultaneously (eg, <a class="drug drug_pediatric" data-topicid="13048" href="/d/drug information/13048.html" rel="external">atomoxetine</a>, <a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">risperidone</a>, and <a class="drug drug_pediatric" data-topicid="12972" href="/d/drug information/12972.html" rel="external">citalopram</a>). It is always good practice to complete a medication interaction analysis when treating patients with more than one medication. </p><p>Specific medication interactions may be determined using the <a class="external" href="/drug-interactions">Lexicomp drug interactions</a> tool included with UpToDate.</p><p class="headingAnchor" id="H9"><span class="h1">TARGET SYMPTOMS</span><span class="headingEndMark"> — </span>Pharmacologic therapy may be warranted for symptom control in children with ASD if behavioral/environmental interventions are ineffective or insufficient for target symptoms. (See <a class="local">'Pretreatment evaluation'</a> above.)</p><p>Target symptoms that may respond to psychotropic medications include [<a href="#rid16">16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperactivity, impulsivity, and inattention</p><p class="bulletIndent1"><span class="glyph">●</span>Maladaptive behaviors/problem behaviors/irritability (eg, aggression, explosive outbursts, self-injury)</p><p class="bulletIndent1"><span class="glyph">●</span>Repetitive behaviors and rigidity</p><p class="bulletIndent1"><span class="glyph">●</span>Anxiety</p><p class="bulletIndent1"><span class="glyph">●</span>Mood lability</p><p class="bulletIndent1"><span class="glyph">●</span>Depression</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Inattention and hyperactivity</span><span class="headingEndMark"> — </span>Children with ASD may be inattentive, hyperactive, and disorganized. These behaviors may be related to comorbid attention deficit hyperactivity disorder (ADHD) or to other factors that affect function in children with ASD (eg, overarousal, anxiety). If the behaviors do not improve with environmental or behavioral interventions, they may respond to pharmacotherapy.</p><p class="headingAnchor" id="H11"><span class="h3">Potential therapies</span><span class="headingEndMark"> — </span>Potential therapies for symptoms of inattention and hyperactivity in children with ASD include stimulant medications (eg, <a class="drug drug_pediatric" data-topicid="12600" href="/d/drug information/12600.html" rel="external">methylphenidate</a>, <a class="drug drug_pediatric" data-topicid="13218" href="/d/drug information/13218.html" rel="external">dextroamphetamine</a>), alpha-2-adrenergic agonists (eg, <a class="drug drug_pediatric" data-topicid="15555" href="/d/drug information/15555.html" rel="external">guanfacine</a>), <a class="drug drug_pediatric" data-topicid="13048" href="/d/drug information/13048.html" rel="external">atomoxetine</a>, atypical antipsychotics (eg, <a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">risperidone</a>), and anticonvulsant mood stabilizers (eg, <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproic acid</a>). There is strong evidence that stimulants and risperidone are beneficial for hyperactivity and marginal evidence for the benefit of other atypical antipsychotics [<a href="#rid17">17</a>].</p><p>Selective serotonin reuptake inhibitors (SSRI) may be helpful if anxiety is contributing to symptoms. SSRI also may be used for repetitive behaviors and depression. They are discussed separately. (See <a class="local">'Anxiety'</a> below and <a class="local">'SSRI'</a> below and <a class="local">'Depression'</a> below.)</p><p class="headingAnchor" id="H3151563"><span class="h4">Stimulants</span><span class="headingEndMark"> — </span>Randomized controlled trials and meta-analyses indicate that stimulant medication improves symptoms in approximately 80 percent of children with ADHD without ASD. (See  <a class="medical medical_review" href="/d/html/16927.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications", section on 'Stimulants versus other medications'</a>.)</p><p><a class="drug drug_pediatric" data-topicid="12600" href="/d/drug information/12600.html" rel="external">Methylphenidate</a> also appears to improve symptoms of hyperactivity and inattention in children with ASD, but the response to methylphenidate is lower in children with ASD than it is in children with isolated ADHD. A systematic review of four-crossover trials (113 children) [<a href="#rid18">18-21</a>] found low quality evidence that short-term treatment with methylphenidate may improve hyperactivity and inattention in children with ASD who can tolerate the medication [<a href="#rid22">22</a>]. In the largest crossover trial, approximately 50 percent of children with ASD responded to methylphenidate (as measured on the hyperactivity subscale of the Aberrant Behavior Checklist [ABC]); the effect size ranged from 0.20 to 0.54, depending upon dose and rater [<a href="#rid20">20</a>], with greater improvement at higher doses [<a href="#rid23">23</a>].</p><p>Studies of amphetamines (<a class="drug drug_pediatric" data-topicid="13218" href="/d/drug information/13218.html" rel="external">dextroamphetamine</a>, <a class="drug drug_pediatric" data-topicid="13219" href="/d/drug information/13219.html" rel="external">dextroamphetamine-amphetamine</a>) in the treatment of attentional symptoms in children with ASD are lacking. It is not clear that the results from trials of <a class="drug drug_pediatric" data-topicid="12600" href="/d/drug information/12600.html" rel="external">methylphenidate</a> can be generalized to amphetamines [<a href="#rid24">24</a>]. However, amphetamines frequently are used in clinical practice.</p><p>The side effects of stimulant medications in children with ASD are similar to those in other patients. However, they occur with greater frequency [<a href="#rid3">3,4</a>]. In a crossover trial of <a class="drug drug_pediatric" data-topicid="12600" href="/d/drug information/12600.html" rel="external">methylphenidate</a> that included 72 children with ASD and hyperactivity, 18 percent of subjects withdrew because of adverse effects [<a href="#rid20">20</a>]. In comparison, in a large, randomized trial of stimulants for attention deficit disorder in children without ASD, the dropout rate was only 3.5 percent [<a href="#rid25">25</a>]. Adverse effects of stimulant medications include, but are not limited to, sleep disturbance, decreased appetite, irritability, tics, sadness, dullness, and social withdrawal. A systematic review of four cross-over trials of methylphenidate in children with ASD could not adequately assess adverse effects because children intolerant to methylphenidate were excluded [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/621.html" rel="external">"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents", section on 'Stimulant adverse effects'</a>.)</p><p class="headingAnchor" id="H3151587"><span class="h4">Alpha agonists</span><span class="headingEndMark"> — </span>Alpha-2-adrenergic agonists (eg, <a class="drug drug_pediatric" data-topicid="15555" href="/d/drug information/15555.html" rel="external">guanfacine</a>, <a class="drug drug_pediatric" data-topicid="13171" href="/d/drug information/13171.html" rel="external">clonidine</a>) also are used to manage symptoms of inattention, hyperactivity, and impulsivity in children with ASD [<a href="#rid4">4,12,24,26</a>].</p><p>Studies of alpha-2-adrenergic agonists are limited, and sample sizes are small. In a multicenter randomized trial comparing extended-release <a class="drug drug_pediatric" data-topicid="15555" href="/d/drug information/15555.html" rel="external">guanfacine</a> with placebo in 62 children with ASD, hyperactivity, impulsiveness, and distractibility, guanfacine was effective in reducing behavioral symptoms [<a href="#rid27">27</a>]. Children receiving guanfacine had greater declines in scores on the ABC-hyperactivity subscale (43.6 versus 13.2 percent) and higher rates of "much improved" or "very much improved" on the Clinical Global Impression-Improvement scale (50 versus 9.4 percent). In an open-label prospective trial of guanfacine in 25 children whose hyperactive symptoms did not respond to <a class="drug drug_pediatric" data-topicid="12600" href="/d/drug information/12600.html" rel="external">methylphenidate</a>, 47 percent responded to guanfacine (decrease in the mean parent- and teacher-rated hyperactivity subscale of the ABC from 31.3 to 19.9 and 29.2 to 22.3, respectively) [<a href="#rid28">28</a>]. Retrospective analysis of guanfacine therapy in 80 children with ASD found guanfacine to be well tolerated with response rates of 27 and 21 percent for symptoms of hyperactivity and inattention, respectively [<a href="#rid26">26</a>]. Adverse effects of guanfacine include sedation, constipation, irritability, and aggression [<a href="#rid26">26,28</a>].</p><p>Two small crossover trials using <a class="drug drug_pediatric" data-topicid="13171" href="/d/drug information/13171.html" rel="external">clonidine</a> suggest decreased irritability, stereotypy, hyperactivity, inappropriate speech, and oppositional behavior [<a href="#rid29">29,30</a>]. However, side effects included hypotension and sedation. It is uncertain whether some of the reduction in symptoms could be attributed to the sedative effect.</p><p>Children who are treated with alpha-2-adrenergic agonists should have their blood pressure and heart rate monitored at each visit. Adverse effects of alpha-2-adrenergic agonists include:</p><p class="bulletIndent1"><span class="glyph">●</span>Sedation</p><p class="bulletIndent1"><span class="glyph">●</span>Hypotension</p><p class="bulletIndent1"><span class="glyph">●</span>Rebound hypertension if discontinued abruptly</p><p class="bulletIndent1"><span class="glyph">●</span>Dry mouth</p><p class="bulletIndent1"><span class="glyph">●</span>Dizziness</p><p class="bulletIndent1"><span class="glyph">●</span>Irritability</p><p class="bulletIndent1"><span class="glyph">●</span>Increased aggression and self-injury</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased appetite</p><p class="bulletIndent1"><span class="glyph">●</span>Sleep disturbance</p><p class="bulletIndent1"><span class="glyph">●</span>Headache</p><p class="bulletIndent1"><span class="glyph">●</span>Nocturnal enuresis</p><p></p><p>Alpha-2-adrenergic agonists can pose significant harm if provided in excess. It is important to counsel parents about the narrow window of therapeutic safety with these medications and to keep all medications secured from children in the home. (See  <a class="medical medical_review" href="/d/html/6509.html" rel="external">"Clonidine, xylazine, and related imidazoline poisoning"</a>.)</p><p class="headingAnchor" id="H3151771"><span class="h4">Atomoxetine</span><span class="headingEndMark"> — </span>Studies of <a class="drug drug_pediatric" data-topicid="13048" href="/d/drug information/13048.html" rel="external">atomoxetine</a> for symptoms of hyperactivity and inattention in children with ASD are limited [<a href="#rid31">31</a>]. In a randomized trial in 97 children (6 to 17 years) with ASD and ADHD, atomoxetine resulted in moderate improvement in ADHD symptoms (eg, reduction in ADHD Rating Scale [ADHD-RS] scores compared with baseline of 8.2 points versus 1.2 point reduction in the placebo group); among the atomoxetine treated patients, improvement was greater on the hyperactivity-impulsivity than on the inattention subscore [<a href="#rid32">32</a>]. However, the difference in the proportion of patients "improved" or "much improved" on the Clinical Global Impression of ADHD Improvement Scale was not statistically significant [<a href="#rid32">32</a>]. Another small randomized crossover trial suggested some improvement in hyperactivity symptoms compared with placebo [<a href="#rid33">33</a>]. However, as with <a class="drug drug_pediatric" data-topicid="12600" href="/d/drug information/12600.html" rel="external">methylphenidate</a>, the overall effect size for atomoxetine in children with ASD and symptoms of ADHD is smaller than for children with ADHD without ASD [<a href="#rid12">12,34,35</a>].</p><p>Side effects of <a class="drug drug_pediatric" data-topicid="13048" href="/d/drug information/13048.html" rel="external">atomoxetine</a> include, but are not limited to, gastrointestinal symptoms, fatigue, sleep problems, mood swings, dizziness, and change in appetite. Rare but potentially serious adverse effects include suicidal ideation and hepatotoxicity. These adverse effects are discussed separately. (See  <a class="medical medical_review" href="/d/html/621.html" rel="external">"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents", section on 'Atomoxetine adverse effects'</a>.)</p><p class="headingAnchor" id="H3151779"><span class="h4">Other drugs</span><span class="headingEndMark"> — </span>Other drugs that may be beneficial for symptoms of hyperactivity and inattention in children with ASD include <a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">risperidone</a> and antiseizure medications [<a href="#rid24">24</a>].</p><p>The use of <a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">risperidone</a> for symptoms of hyperactivity in children with ASD is supported by open-label and randomized controlled trials [<a href="#rid24">24,36,37</a>]. In a multicenter, placebo-controlled trial of 101 children with autism, treatment with risperidone (1.8 mg/day) for eight weeks was associated with decreased mean scores on the hyperactivity subscale of the ABC compared with baseline (32 to 17 versus 32 to 28 in the placebo group) [<a href="#rid36">36</a>].</p><p><a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">Risperidone</a> also may be used for a range of maladaptive behaviors including irritability, stereotypy, aggression, explosive outbursts, and self-injury and is discussed separately. (See <a class="local">'Risperidone'</a> below.)</p><p>The evidence for antiseizure agents (<a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproate</a>, <a class="drug drug_pediatric" data-topicid="12851" href="/d/drug information/12851.html" rel="external">topiramate</a>, <a class="drug drug_pediatric" data-topicid="12542" href="/d/drug information/12542.html" rel="external">lamotrigine</a>) is limited to small, open-label, or observational studies [<a href="#rid38">38-40</a>].</p><p class="headingAnchor" id="H12"><span class="h3">Approach</span><span class="headingEndMark"> — </span>When, after a discussion of the potential risks and benefits, the clinician and parents agree that pharmacotherapy is indicated for symptoms of inattention, hyperactivity, and impulsivity that continue to impair function despite behavioral and environmental interventions and are not thought to be related to other symptoms (eg, anxiety), a trial of a stimulant (usually <a class="drug drug_pediatric" data-topicid="12600" href="/d/drug information/12600.html" rel="external">methylphenidate</a>) may be beneficial. An alternative agent may be chosen if stimulant therapy is not effective or there are other target symptoms that require pharmacologic intervention (eg, <a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">risperidone</a> if disruptive behaviors secondary to irritability also require treatment). This approach is consistent with that in the Autism Speaks Autism Treatment Network Psychopharmacology Committee clinical practice pathway for evaluation and medication choice for ADHD symptoms in children with ASD [<a href="#rid41">41</a>].</p><p>If <a class="drug drug_pediatric" data-topicid="12600" href="/d/drug information/12600.html" rel="external">methylphenidate</a> is not tolerated, a trial of another stimulant, <a class="drug drug_pediatric" data-topicid="13048" href="/d/drug information/13048.html" rel="external">atomoxetine</a>, or alpha-agonist may be warranted [<a href="#rid8">8,41</a>]. (See  <a class="medical medical_review" href="/d/html/16927.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications", section on 'Choice of agent'</a> and  <a class="medical medical_review" href="/d/html/621.html" rel="external">"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents", section on 'Introduction'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Maladaptive/problem behaviors</span><span class="headingEndMark"> — </span>Maladaptive behaviors in children with ASD include irritability, aggression, explosive outbursts (tantrums), and self-injury. These behaviors may occur in response to anxiety or frustration, which should be the first targets of management [<a href="#rid3">3</a>]. Maladaptive behaviors also can be due to anxiety, mood disorders, or impulse control problems; if one of these conditions is identified as a cause for the behavior, medications that target that symptom should be used. (See <a class="local">'Anxiety'</a> below and <a class="local">'Mood lability'</a> below and <a class="local">'Depression'</a> below and <a class="local">'Inattention and hyperactivity'</a> above.)</p><p>Pharmacotherapy may be indicated if nonpharmacologic therapies are unsuccessful. Combined pharmacologic and nonpharmacologic interventions may be more beneficial than medication alone [<a href="#rid42">42,43</a>]. The pharmacologic agent of choice to treat the behavior depends upon the postulated cause of the disruptive behavior.</p><p class="headingAnchor" id="H14"><span class="h3">Potential agents</span><span class="headingEndMark"> — </span>The atypical antipsychotic agents, <a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">risperidone</a> and <a class="drug drug_pediatric" data-topicid="13180" href="/d/drug information/13180.html" rel="external">aripiprazole</a> [<a href="#rid11">11</a>], are the only medications approved by the US Food and Drug Administration (FDA) to treat irritability and self-injurious and aggressive behaviors in children with ASD. Agents that are used off-label include other atypical antipsychotics (<a class="drug drug_pediatric" data-topicid="16033" href="/d/drug information/16033.html" rel="external">olanzapine</a>, <a class="drug drug_pediatric" data-topicid="12995" href="/d/drug information/12995.html" rel="external">clozapine</a>, <a class="drug drug_pediatric" data-topicid="89427" href="/d/drug information/89427.html" rel="external">quetiapine</a>, <a class="drug drug_pediatric" data-topicid="15622" href="/d/drug information/15622.html" rel="external">ziprasidone</a>), <a class="drug drug_pediatric" data-topicid="13347" href="/d/drug information/13347.html" rel="external">haloperidol</a> (a typical antipsychotic), antiseizure medications, alpha-2 agonists, mood stabilizers, SSRI, and beta-blockers. There is strong evidence that risperidone and aripiprazole are beneficial for disruptive behaviors and marginal evidence for benefit with other atypical antipsychotics, antiseizure medications, psychostimulants, and <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> [<a href="#rid17">17,44</a>].</p><p class="headingAnchor" id="H3151821"><span class="h4">Risperidone</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">Risperidone</a> is the most commonly used antipsychotic for the treatment of maladaptive behaviors in children with ASD [<a href="#rid45">45</a>]. It is approved by the FDA for the treatment of irritability presenting with aggression, tantrums, and/or deliberate self-injury in children (≥5 years) with ASD.</p><p>Randomized controlled trials and systematic reviews indicate a positive response to <a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">risperidone</a> in individuals with autism and disruptive behaviors [<a href="#rid36">36,37,44,46-51</a>]. In a multicenter, placebo-controlled trial of 101 children with autism and maladaptive behaviors, treatment with risperidone (1.8 mg/day) for eight weeks was associated with [<a href="#rid36">36,52,53</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Higher treatment response; treatment response was defined as 25 percent or greater decrease in the irritability score and rating of "much improved" or "very much improved" on the Clinical Global Impression-Improvement (CGI-I) scale (69 versus 12 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Greater proportion "much improved" or "very much improved" on the CGI-I scale compared with baseline (75 versus 11 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Greater decrease in mean irritability score compared with baseline (57 versus 14 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improvements in repetitive behaviors and restricted interests, but no effects on social function or communication (in secondary analysis) [<a href="#rid52">52</a>] (see <a class="local">'Repetitive behaviors and rigidity'</a> below)</p><p></p><p>Dosing of risperidone is discussed separately. See <a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">Risperidone</a> drug information.</p><p>Adverse effects of <a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">risperidone</a> included weight gain, increased appetite, fatigue, drowsiness, dizziness, drooling, tremor, and constipation. However, they were mild and resolved over a few weeks [<a href="#rid36">36</a>]. There was no increase in tardive dyskinesia or other extrapyramidal symptoms compared with the placebo group. No additional adverse effects were noted during the four-month open-label continuation phase [<a href="#rid54">54</a>]. In postmarketing surveillance, there have been reports of cases of extrapyramidal symptoms with concomitant use of risperidone and <a class="drug drug_pediatric" data-topicid="12600" href="/d/drug information/12600.html" rel="external">methylphenidate</a> or <a class="drug drug_pediatric" data-topicid="13010" href="/d/drug information/13010.html" rel="external">dexmethylphenidate</a> with changes to the regimen of one or both medications (eg, initiation, discontinuation, increased dose, decreased dose) [<a href="#rid55">55,56</a>]. Close surveillance is warranted with any of these changes. This drug interaction is discussed in the <a class="external" href="/drug-interactions">Lexicomp drug interactions</a> program included with UpToDate.</p><p>Adverse effects of atypical antipsychotics and monitoring for adverse effects are discussed in greater detail below. (See <a class="local">'Side effects of antipsychotics'</a> below.)</p><p class="headingAnchor" id="H3152019"><span class="h4">Aripiprazole</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13180" href="/d/drug information/13180.html" rel="external">Aripiprazole</a> is approved by the FDA for the treatment of irritability in children (aged 6 to 17 years) with ASD [<a href="#rid11">11</a>].</p><p>In multicenter randomized trials, flexible and fixed dosing regimens of <a class="drug drug_pediatric" data-topicid="13180" href="/d/drug information/13180.html" rel="external">aripiprazole</a> for eight weeks were beneficial in reducing irritability, stereotypy, and hyperactivity in children (aged 6 to 17 years) with autism and irritability (as measured by the ABC and Clinical Global Impressions-Severity scale) [<a href="#rid57">57-59</a>]. In another multicenter randomized trial, among 85 patients who had a stable response to 12 weeks of aripiprazole and were randomly assigned to continuation of aripiprazole or to placebo, the time to relapse did not differ between groups [<a href="#rid60">60</a>]. Given that the efficacy of aripiprazole for the maintenance treatment of irritability in children with autism has not been established, it is important to periodically re-evaluate the need for continued treatment [<a href="#rid11">11</a>].</p><p>Adverse effects of <a class="drug drug_pediatric" data-topicid="13180" href="/d/drug information/13180.html" rel="external">aripiprazole</a> included fatigue, vomiting, somnolence, weight gain, tremor, and extrapyramidal symptoms [<a href="#rid15">15,57,58</a>]. With the fixed-dose regimen, approximately 10 percent of subjects withdrew because of adverse events; serious adverse events occurred in two subjects (presyncope and aggression) [<a href="#rid58">58</a>].</p><p>Development of new impulse-control problems or uncontrollable urges (eg, gambling, binge eating) also have been reported rarely in adults and children [<a href="#rid61">61</a>]. Indications for <a class="drug drug_pediatric" data-topicid="13180" href="/d/drug information/13180.html" rel="external">aripiprazole</a> in the reported cases included, but were not limited to, schizophrenia, schizoaffective disorder, bipolar mood disorder, major depressive disorder, and anxiety disorder; ASD was not specifically mentioned. Children receiving aripiprazole should be monitored for impulse-control problems; this may be challenging in those with lower cognitive and language function.</p><p>Adverse effects of atypical antipsychotics and monitoring for adverse effects are discussed in greater detail below. (See <a class="local">'Side effects of antipsychotics'</a> below.)</p><p class="headingAnchor" id="H3152108"><span class="h4">Olanzapine</span><span class="headingEndMark"> — </span>Several small prospective studies (only one of which was blinded) demonstrated clinical improvement in disruptive behaviors in children with ASD who were treated with <a class="drug drug_pediatric" data-topicid="16033" href="/d/drug information/16033.html" rel="external">olanzapine</a> (an atypical antipsychotic) [<a href="#rid62">62-65</a>]. However, weight gain and other side effects, such as sedation, often prohibit continued use of olanzapine. The risk of extrapyramidal side effects with olanzapine appears to be low.</p><p class="headingAnchor" id="H3152116"><span class="h4">Other atypical antipsychotics</span><span class="headingEndMark"> — </span>Other atypical antipsychotics (eg, <a class="drug drug_pediatric" data-topicid="12995" href="/d/drug information/12995.html" rel="external">clozapine</a>, <a class="drug drug_pediatric" data-topicid="89427" href="/d/drug information/89427.html" rel="external">quetiapine</a>, <a class="drug drug_pediatric" data-topicid="15622" href="/d/drug information/15622.html" rel="external">ziprasidone</a>) are used in clinical practice to treat disruptive behaviors in children with ASD. The evidence to support the use of these agents consists primarily of open-label studies or case series [<a href="#rid66">66-69</a>]. Additional research is needed before they can be recommended as the initial medical therapy for disruptive behavior in children with ASD.</p><p class="headingAnchor" id="H3152124"><span class="h4">Haloperidol</span><span class="headingEndMark"> — </span>Randomized controlled trials suggest that <a class="drug drug_pediatric" data-topicid="13347" href="/d/drug information/13347.html" rel="external">haloperidol</a>, a typical antipsychotic, is effective in the treatment of behavioral symptoms (tantrums, aggression, hyperactivity, social withdrawal, and stereotypies) in children with ASD [<a href="#rid70">70,71</a>]. However, it is less effective than <a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">risperidone</a> [<a href="#rid71">71</a>]. In addition, the risk of dyskinesia and other extrapyramidal symptoms (in approximately one-third of patients) limits its use [<a href="#rid72">72</a>].</p><p>Children who are treated with <a class="drug drug_pediatric" data-topicid="13347" href="/d/drug information/13347.html" rel="external">haloperidol</a> should be monitored closely. A drug holiday may be warranted to avoid dyskinesia. Haloperidol should be slowly weaned to prevent withdrawal dyskinesia. The optimal duration of drug holiday is unclear.</p><p class="headingAnchor" id="H3152132"><span class="h4">Other agents</span><span class="headingEndMark"> — </span>Alpha-2 agonists (specifically <a class="drug drug_pediatric" data-topicid="13171" href="/d/drug information/13171.html" rel="external">clonidine</a>) and <a class="drug drug_pediatric" data-topicid="13239" href="/d/drug information/13239.html" rel="external">N-acetylcysteine</a> have demonstrated some improvement in symptoms with fewer side effects than atypical anti-psychotics in small, individual studies; however, additional research is needed [<a href="#rid44">44</a>]. Antiseizure medications, mood stabilizers (eg, <a class="drug drug_pediatric" data-topicid="12559" href="/d/drug information/12559.html" rel="external">lithium</a>), SSRI, stimulants, and beta blockers have been used to treat disruptive behaviors in children and adolescents with ASD [<a href="#rid12">12,44,73</a>].</p><p class="headingAnchor" id="H15"><span class="h3">Side effects of antipsychotics</span><span class="headingEndMark"> — </span>The use of antipsychotic agents often is limited by their side effect profile. Side effects of atypical antipsychotics may include, but are not limited to [<a href="#rid8">8,74-77</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased appetite</p><p class="bulletIndent1"><span class="glyph">●</span>Weight gain</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated blood sugar secondary to insulin resistance</p><p class="bulletIndent1"><span class="glyph">●</span>Dyslipidemia</p><p class="bulletIndent1"><span class="glyph">●</span>Blood pressure changes</p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiogram (EKG) changes, such as prolongation of QTc (more common with <a class="drug drug_pediatric" data-topicid="15622" href="/d/drug information/15622.html" rel="external">ziprasidone</a> [<a href="#rid78">78</a>])</p><p class="bulletIndent1"><span class="glyph">●</span>Fatigue and drowsiness</p><p class="bulletIndent1"><span class="glyph">●</span>Dizziness</p><p class="bulletIndent1"><span class="glyph">●</span>Drooling</p><p class="bulletIndent1"><span class="glyph">●</span>Liver function abnormalities</p><p class="bulletIndent1"><span class="glyph">●</span>Increase in prolactin (of unknown clinical significance)</p><p class="bulletIndent1"><span class="glyph">●</span>Gynecomastia</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac conduction effects (prolonged QTc)</p><p></p><p>Less common, but serious, side effects include dystonic reactions, tardive dyskinesia, akathisia (subjective sense of restlessness, often accompanied by voluntary movements of the limbs or trunk), neuroleptic malignant syndrome, and agranulocytosis (with <a class="drug drug_pediatric" data-topicid="12995" href="/d/drug information/12995.html" rel="external">clozapine</a>) [<a href="#rid36">36,46,69,79</a>].</p><p>Children who are treated with atypical antipsychotic agents should be monitored regularly. At baseline, the child's weight and height should be measured and body mass index calculated ((<a class="calc calc_professional" href="/d/html/13412.html" rel="external">calculator 1</a>) [for boys] and (<a class="calc calc_professional" href="/d/html/13415.html" rel="external">calculator 2</a>) [for girls]) [<a href="#rid80">80</a>]. Given the cardiometabolic side effects, it is important to take a thorough patient and family history, asking specifically about obesity, diabetes, dyslipidemia, hypertension, and cardiovascular disease. A baseline EKG should be obtained; the EKG should be repeated when the patient has reached the steady state (particularly in patients treated with <a class="drug drug_pediatric" data-topicid="15622" href="/d/drug information/15622.html" rel="external">ziprasidone</a>).</p><p>Follow-up visits should include measurement of weight and blood pressure and evaluation for extrapyramidal findings (the use of a scale, such as the Abnormal Involuntary Movement Scale [available online from various websites], is helpful). Baseline and follow-up laboratory studies may include fasting plasma glucose, fasting lipids, complete blood count, liver function tests, thyroid stimulating hormone (TSH), prolactin, and electrolytes.</p><p>The optimal frequency of laboratory monitoring is not clear. We suggest follow-up at three months after starting medication and every six months thereafter for most of the studies listed above and when doses are increased. Prolactin and TSH may be monitored less frequently unless symptoms of abnormalities arise. More frequent testing may be necessary if metabolic abnormalities are identified.</p><p class="headingAnchor" id="H16"><span class="h3">Treatment approach</span><span class="headingEndMark"> — </span>As with most psychopharmacologic agents used in children with ASD, there are few published clinical guidelines regarding medication use for disruptive or maladaptive behavior such as irritability, aggression, impulsivity, tantrums, and/or deliberate self-injury in children with ASD [<a href="#rid51">51</a>]. The treatment of disruptive behaviors in children with ASD involves a tradeoff between benefits and risks [<a href="#rid81">81</a>]. <a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">Risperidone</a> and <a class="drug drug_pediatric" data-topicid="13180" href="/d/drug information/13180.html" rel="external">aripiprazole</a> may be beneficial for aggression and self-injury that are not thought to be related to other symptoms (eg, anxiety) [<a href="#rid37">37,48</a>]. Other medications (eg, stimulants, SSRI, alpha-adrenergic agonists) may be more appropriate, depending upon the underlying cause of aggression and self-injury (eg, hyperactivity, anxiety, impulsivity).</p><p>Other atypical antipsychotic agents (eg, <a class="drug drug_pediatric" data-topicid="12995" href="/d/drug information/12995.html" rel="external">clozapine</a>, <a class="drug drug_pediatric" data-topicid="16033" href="/d/drug information/16033.html" rel="external">olanzapine</a>, <a class="drug drug_pediatric" data-topicid="89427" href="/d/drug information/89427.html" rel="external">quetiapine</a>, <a class="drug drug_pediatric" data-topicid="15622" href="/d/drug information/15622.html" rel="external">ziprasidone</a>) and different classes of drugs (eg, alpha-2 agonists, antiseizure medications, mood stabilizers, SSRI, and beta blockers) have been used to treat disruptive behaviors in children and adolescents with ASD [<a href="#rid12">12</a>]. However, there is less evidence to support the use of these agents for this indication.</p><p>Switching to another antipsychotic agent is commonly recommended if there is excessive weight gain or other adverse effects. However, discontinuation of medication may be warranted depending upon symptom severity. This is especially true if the individual has been treated for a long interval (ie, a year or more) and would benefit from a trial off medications to reassess efficacy and need for treatment. Withdrawal of <a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">risperidone</a> and other antipsychotics is often accompanied by a period of greater behavioral dysregulation. Successful discontinuation of risperidone and other antipsychotic agents requires a gradual taper over several weeks to months. (See <a class="local">'General principles'</a> above.)</p><p class="headingAnchor" id="H17"><span class="h2">Repetitive behaviors and rigidity</span><span class="headingEndMark"> — </span>Repetitive behaviors, stereotypies, and rigidity in children with ASD often interfere with function.</p><p class="headingAnchor" id="H3288299832"><span class="h3">Approach</span><span class="headingEndMark"> — </span>Repetitive behaviors and rigidity are core symptoms of ASD. They also can be exacerbated by anxiety or other conditions. Medication may be warranted if the behaviors interfere with function and have not responded adequately to nonpharmacologic interventions (eg, behavior therapy). Pharmacologic treatment involves a tradeoff between benefits and risks [<a href="#rid81">81</a>]. The literature is limited by the lack of tools that specifically measure stereotypies and rigidity. Many studies measure obsessive-compulsive behaviors, which may not be the best proxy for stereotypies and rigidity in children with ASD.</p><p>When medication is necessary for children with ASD and repetitive behaviors and rigidity that are thought to be related to anxiety, clinical practice suggests the use of <a class="drug drug_pediatric" data-topicid="13315" href="/d/drug information/13315.html" rel="external">fluoxetine</a>, <a class="drug drug_pediatric" data-topicid="12787" href="/d/drug information/12787.html" rel="external">sertraline</a>, or another SSRI as the initial medication. Despite the lack of high-quality evidence that SSRIs are directly beneficial for repetitive behaviors and rigidity in children with ASD [<a href="#rid82">82</a>], they may be indirectly helpful by reducing anxiety. In addition, SSRIs have fewer serious adverse effects than other potential treatments. It is unclear whether SSRIs are helpful for stereotypies and rigidity without comorbid anxiety. (See <a class="local">'SSRI'</a> below and <a class="local">'Anxiety'</a> below.)</p><p class="headingAnchor" id="H18"><span class="h3">Potential treatments</span><span class="headingEndMark"> — </span>Potential treatments for repetitive behaviors in children with ASD include SSRI, <a class="drug drug_pediatric" data-topicid="13050" href="/d/drug information/13050.html" rel="external">clomipramine</a>, atypical antipsychotics, <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproate</a>, and <a class="drug drug_pediatric" data-topicid="13102" href="/d/drug information/13102.html" rel="external">buspirone</a>, although high-quality evidence to support these therapies is lacking [<a href="#rid17">17</a>]. <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">Naltrexone</a>, <a class="drug drug_pediatric" data-topicid="12784" href="/d/drug information/12784.html" rel="external">secretin</a>, and stimulants have been shown to be ineffective [<a href="#rid17">17</a>]. </p><p class="headingAnchor" id="H4231702236"><span class="h4">SSRI</span><span class="headingEndMark"> — </span>The use of selective serotonin reuptake inhibitors (SSRI) for repetitive behaviors in children with ASD is based upon the effectiveness of SSRI in individuals with obsessive-compulsive disorder (OCD), demonstrated in meta-analysis of randomized controlled trials [<a href="#rid83">83</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13315" href="/d/drug information/13315.html" rel="external">Fluoxetine</a> – Evidence regarding fluoxetine for repetitive behaviors in children with ASD is mixed. In a multicenter trial in 146 children (age 7.5 to 18 years) with ASD and a score of ≥6 on the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), a 20-point scale with a minimal clinically important difference of two points, who were randomly assigned to 16 weeks of fluoxetine or placebo, a clinically important difference was not detected after prespecified adjustment for potential confounding factors (eg, sex, verbal ability) [<a href="#rid84">84</a>]. CY-BOCS scores decreased from baseline in both groups (from 12.8 to 9.02 in the fluoxetine group and from 13.13 to 10.89 in the placebo group; adjusted mean difference between groups -1.17, 95% CI -3.01 to 0.67). Another multicenter randomized trial in 158 children (age 5 to 17 years) with ASD also did not detect a clinically important difference in CY-BOCS scores between very low dose fluoxetine and placebo groups; similar proportions of children achieved &gt;25 percent reduction in CY-BOCS from baseline (36 and 41 percent, respectively) [<a href="#rid85">85</a>]. In an earlier randomized, placebo-controlled crossover study in 44 children with ASD, fluoxetine was beneficial in reducing repetitive behaviors as measured on the CY-BOCS [<a href="#rid86">86</a>]. </p><p></p><p class="bulletIndent1">The frequency and severity of adverse effects was similar with <a class="drug drug_pediatric" data-topicid="13315" href="/d/drug information/13315.html" rel="external">fluoxetine</a> and placebo [<a href="#rid84">84,85</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13025" href="/d/drug information/13025.html" rel="external">Fluvoxamine</a> – In an unpublished randomized trial in children, fluvoxamine had limited efficacy in reducing repetitive behaviors and was poorly tolerated [<a href="#rid87">87</a>]. However, it may be beneficial in adults with ASD [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12787" href="/d/drug information/12787.html" rel="external">Sertraline</a> – Open-label trials of sertraline in adults with ASD have noted improvements in repetitive and disruptive behaviors [<a href="#rid89">89,90</a>]. There are no randomized controlled trials in adults or children.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12681" href="/d/drug information/12681.html" rel="external">Paroxetine</a> – Studies of paroxetine in children with ASD are lacking. Small open-label studies in individuals with intellectual disability suggest that it may be beneficial in reducing aggression [<a href="#rid91">91</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12972" href="/d/drug information/12972.html" rel="external">Citalopram</a> – In a multicenter randomized trial in 149 children with ASD, citalopram did not improve repetitive behaviors and was associated with increased risk of adverse events, including increased energy level, impulsiveness, decreased concentration, hyperactivity, stereotypy, diarrhea, insomnia, dry skin, and pruritus [<a href="#rid92">92</a>]. Citalopram also may cause cardiac conduction effects (prolonged QTc).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13043" href="/d/drug information/13043.html" rel="external">Escitalopram</a> – An open-label trial of escitalopram demonstrated some improvement in irritability, lethargy, stereotypy, hyperactivity, and inappropriate speech [<a href="#rid93">93</a>]. There was a wide variability in therapeutic dose that was not related to patient weight.</p><p></p><p class="bulletIndent1">Children taking SSRI should be monitored for adverse effects, including activation, sedation, anorexia, agitation, headaches, aggression, anxiety activation, insomnia, gastrointestinal upset, and drowsiness. Blood pressure and heart rate should be monitored at follow-up visits.</p><p></p><p class="bulletIndent1">When used in children and adolescents with depression, SSRI have been associated with increased suicidal ideation (see  <a class="medical medical_review" href="/d/html/1225.html" rel="external">"Effect of antidepressants on suicide risk in children and adolescents"</a>). Increased suicidal ideation has not been demonstrated in studies of SSRI in individuals with ASD. However, most studies did not assess suicidal ideation and included too few subjects to detect rare adverse effects, such as suicidal ideation.</p><p></p><p class="headingAnchor" id="H629215218"><span class="h4">Clomipramine</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13050" href="/d/drug information/13050.html" rel="external">Clomipramine</a> is a serotonin-selective tricyclic antidepressant. The use of clomipramine for repetitive behaviors in children with ASD is based upon its effectiveness in individuals with OCD, as demonstrated in controlled trials [<a href="#rid94">94</a>].However, studies of clomipramine for repetitive behavior in children with ASD have inconsistent findings [<a href="#rid95">95-97</a>]. The use of clomipramine often is limited by its side effects, which may include lethargy, tremors, tachycardia, insomnia, diaphoresis, nausea, decreased appetite, urinary retention, and severe constipation.</p><p class="headingAnchor" id="H17056199"><span class="h4">Risperidone</span><span class="headingEndMark"> — </span>In secondary analysis of a multicenter placebo-controlled trial of 101 children with autism and disruptive behavior, treatment with <a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">risperidone</a> (1.8 mg/day) for eight weeks was associated with greater decrease in mean CY-BOCS compulsion scale (15.5 to 11.65 versus 15.2 to 14.2) [<a href="#rid52">52</a>]. Adverse effects of risperidone are discussed above. (See <a class="local">'Side effects of antipsychotics'</a> above.)</p><p class="headingAnchor" id="H2182996184"><span class="h4">Valproate</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">Valproate</a>, an antiseizure medication, is also used to treat repetitive behaviors in children with ASD. It use is supported by a small, blinded randomized controlled trial that demonstrated improvement in repetitive behaviors as measured by the CY-BOCS [<a href="#rid98">98</a>].</p><p>Side effects of <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproic acid</a> may include, but are not limited to, irritability, weight gain, anxiety, and aggression. The pharmacology and use of valproate is discussed separately. (See  <a class="medical medical_review" href="/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Valproate'</a>.)</p><p class="headingAnchor" id="H3753832303"><span class="h4">Buspirone</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13102" href="/d/drug information/13102.html" rel="external">Buspirone</a>, an anxiolytic, is a serotonin partial agonist. In a randomized trial comparing two doses of buspirone with placebo in 166 children with ASD, low-dose buspirone (2.5 mg twice per day) had no effect on core symptoms of ASD (as assessed with the Autism Diagnostic Observation Schedule [ADOS] Composite Total Score), but improved scores on the ADOS Restricted and Repetitive Behavior score (a secondary outcome) [<a href="#rid99">99</a>]. Although these results suggest that buspirone may be a useful adjunct to behavioral interventions for the treatment of repetitive behaviors, additional study is necessary.</p><p class="headingAnchor" id="H19"><span class="h2">Anxiety</span><span class="headingEndMark"> — </span>Anxiety is common in individuals with ASD and may contribute to aggressive, explosive, or self-injurious behaviors. (See <a class="local">'Maladaptive/problem behaviors'</a> above.)</p><p>Anxiety in children with ASD is treated with the same therapies that are used to treat anxiety in other children. Pharmacotherapy is one arm of a multimodal approach that may include individual therapy, cognitive behavioral therapy, behavioral interventions/incentives; accommodations to address sensory sensitivities; and special education services [<a href="#rid100">100-103</a>]. The components of the multimodal therapy may vary from patient to patient. (See  <a class="medical medical_review" href="/d/html/15927.html" rel="external">"Psychotherapy for anxiety disorders in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/15928.html" rel="external">"Pharmacotherapy for anxiety disorders in children and adolescents"</a>.)</p><p>Symptoms related to anxiety in children with ASD often are treated with SSRI. There are no randomized trials that specifically assess the efficacy of SSRI in individuals with ASD. However, in a meta-analysis of randomized controlled trials in children without ASD, SSRI were more effective than placebo in reducing core symptoms of anxiety in children and adolescents (58 versus 31 percent, relative risk of response 1.9, 95% CI 1.6-2.26) [<a href="#rid104">104</a>]. (See <a class="local">'SSRI'</a> above.)</p><p>The use of SSRI in children with repetitive behaviors is discussed above. (See <a class="local">'SSRI'</a> above.)</p><p><a class="drug drug_pediatric" data-topicid="13102" href="/d/drug information/13102.html" rel="external">Buspirone</a> (an anxiolytic), and <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a> (an alpha-2 antagonist) are other agents that may be used to treat anxiety in children with ASD [<a href="#rid99">99,105,106</a>].</p><p class="headingAnchor" id="H20"><span class="h2">Mood lability</span><span class="headingEndMark"> — </span>A number of agents have been used to treat dysregulated mood and symptoms related to dysregulated mood in children and adolescents with ASD. These include atypical antipsychotics, SSRI, and mood-stabilizing agents (eg, <a class="drug drug_pediatric" data-topicid="12559" href="/d/drug information/12559.html" rel="external">lithium</a>). None of these agents has been studied specifically for mood regulation in children with ASD.</p><p>Atypical antipsychotics also may be used to treat maladaptive behaviors. Their use is discussed above. (See <a class="local">'Treatment approach'</a> above and <a class="local">'Side effects of antipsychotics'</a> above.)</p><p>SSRI also may be used to treat repetitive behaviors and anxiety. Their use is discussed above. (See <a class="local">'SSRI'</a> above.)</p><p class="headingAnchor" id="H21"><span class="h2">Depression</span><span class="headingEndMark"> — </span>Antidepressant therapy may be indicated if depressive symptoms persist despite counseling and psychosocial interventions. The same medications that are used for depression in typical children can be used to treat symptoms of depression in children with ASD. (See  <a class="medical medical_review" href="/d/html/1227.html" rel="external">"Pediatric unipolar depression and pharmacotherapy: Choosing a medication"</a>.)</p><p>The efficacy of SSRI and serotonin norepinephrine reuptake inhibitors (SNRI) in the treatment of children with ASD and depression has not been documented through a sufficient number of randomized controlled trials to draw any firm conclusions [<a href="#rid107">107</a>]. Nonetheless, SSRI/SNRI may be warranted for patients who demonstrate clear symptoms of depression (eg, terminal insomnia, psychomotor disturbance, anorexia, changes in mood from baseline, etc). (See  <a class="medical medical_review" href="/d/html/1224.html" rel="external">"Pediatric unipolar depression: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p>When using antidepressants to treat depressive symptoms in children and adolescents with ASD, the clinician must be mindful of the increased incidence of behavioral activation (impulsivity, silliness, agitation, and disinhibition) and other side effects, including a potentially increased risk of suicidal ideation. (See  <a class="medical medical_review" href="/d/html/1227.html" rel="external">"Pediatric unipolar depression and pharmacotherapy: Choosing a medication", section on 'Adverse side effects'</a> and  <a class="medical medical_review" href="/d/html/1225.html" rel="external">"Effect of antidepressants on suicide risk in children and adolescents"</a>.)</p><p>Individuals with ASD may respond to very low doses of SSRI/SNRI, but typical pediatric doses may be necessary. It is important to "start low and go slow." (See <a class="local">'Overview'</a> above.)</p><p class="headingAnchor" id="H695061067"><span class="h2">Other psychiatric conditions</span><span class="headingEndMark"> — </span>Individuals with ASD may have other coexisting psychiatric conditions that can be challenging to diagnose. As an example, disorders with disorganized thought, delusions, or hallucinations may be difficult to diagnose in children with ASD. Referral to a psychiatrist is suggested for children and adolescents with ASD who are suspected to have an emerging thought disorder. Treatment of psychosis in children with ASD is similar to that in children without ASD.</p><p class="headingAnchor" id="H22"><span class="h1">INVESTIGATIVE THERAPIES FOR SOCIAL DEFICITS</span></p><p class="headingAnchor" id="H3337790825"><span class="h2">Oxytocin</span><span class="headingEndMark"> — </span>Although small or open-label studies suggested that oxytocin may improve social interaction or function in children with ASD [<a href="#rid108">108-113</a>], a blinded, randomized trial did not detect a benefit [<a href="#rid114">114</a>]. Among 290 children with ASD (age 3 to 17 years, stratified for age and verbal fluency) randomly assigned to a 24-week course of intranasal oxytocin (target dose of 48 international units daily) or placebo, the least-squares mean change from baseline scores on the Aberrant Behavior Checklist modified Social Withdrawal subscale (ABC-mSW) were similar (-3.7 to -3.5, mean difference -0.2, 95% CI -1.5 to 1.0). The ABC-mSW consists of 13 items, scores range from 0 to 13, and higher scores indicate less social interaction. Secondary measures of social interaction, including the Social Responsiveness Scale-2 Social Motivation subscale, Sociability Factor, and Stanford–Binet Intelligence Scale: Fifth Edition Abbreviated IQ, were also assessed, given the difficulty of capturing changes in social function over time. The least-squares mean change from baseline scores on the secondary measures were also similar between groups. In subgroup analysis, no difference was detected among participants with fluent verbal speech, among participants with minimal verbal fluency, or when analyzed according to baseline oxytocin levels.</p><p>Additional randomized trials are necessary before oxytocin can be recommended to improve social interaction in children with ASD.</p><p class="headingAnchor" id="H2497992569"><span class="h2">Other investigative therapies</span><span class="headingEndMark"> — </span>Other pharmacologic agents that demonstrated potential benefit for social deficits in individuals with ASD in small or open-label studies include D-cycloserine [<a href="#rid115">115</a>], tetrahydrobiopterin [<a href="#rid116">116</a>], and cognition enhancers used in the treatment of Alzheimer disease (eg, <a class="drug drug_general" data-topicid="8739" href="/d/drug information/8739.html" rel="external">galantamine</a>, <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a>, and <a class="drug drug_general" data-topicid="9529" href="/d/drug information/9529.html" rel="external">rivastigmine</a>) [<a href="#rid17">17,117-122</a>]. Additional controlled studies are necessary to confirm efficacy and safety before these therapies can be recommended.</p><p><a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">Naltrexone</a> has been shown to be ineffective in the treatment of social deficits [<a href="#rid17">17,122</a>].</p><p class="headingAnchor" id="H25"><span class="h1">ASSOCIATED CONDITIONS</span></p><p class="headingAnchor" id="H26"><span class="h2">Seizures</span><span class="headingEndMark"> — </span>Seizures are more common in children with ASD than in the general population (see  <a class="medical medical_review" href="/d/html/595.html" rel="external">"Autism spectrum disorder (ASD) in children and adolescents: Terminology, epidemiology, and pathogenesis", section on 'Associated conditions and syndromes'</a>). Pharmacologic management of seizures in children with ASD is similar to that of seizures in children without ASD. (See  <a class="medical medical_review" href="/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring"</a>.)</p><p class="headingAnchor" id="H27"><span class="h2">Gastrointestinal problems</span><span class="headingEndMark"> — </span>A 2014 meta-analysis found a higher prevalence of gastrointestinal (GI) symptoms in children with ASD than in the general population [<a href="#rid123">123</a>]. The American Academy of Pediatrics and Scottish Intercollegiate Guidelines Network recommended that GI disorders in children with an ASD generally should be managed in the same way as in children without an ASD [<a href="#rid8">8,124</a>]. However, because children with ASD may not tolerate certain aspects of the examination or types of diagnostic studies (eg, rectal examination), trials of pharmacologic therapy for constipation or gastroesophageal reflux may be undertaken based upon symptoms [<a href="#rid124">124</a>].</p><p>Pharmacologic interventions for specific GI problems in children are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Constipation (see  <a class="medical medical_review" href="/d/html/5873.html" rel="external">"Chronic functional constipation and fecal incontinence in infants, children, and adolescents: Treatment"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastroesophageal reflux disease (see  <a class="medical medical_review" href="/d/html/5900.html" rel="external">"Management of gastroesophageal reflux disease in children and adolescents"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic abdominal pain (see  <a class="medical medical_review" href="/d/html/112.html" rel="external">"Functional abdominal pain in children and adolescents: Management in primary care"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic diarrhea (see  <a class="medical medical_review" href="/d/html/5881.html" rel="external">"Approach to chronic diarrhea in children &gt;6 months in resource-abundant settings"</a>)</p><p></p><p class="headingAnchor" id="H28"><span class="h2">Sleep disturbance</span><span class="headingEndMark"> — </span>Many children with ASD have associated sleep problems or disorders, including bedtime resistance, sleep anxiety, sleep-onset disturbances, frequent waking, restlessness, or abnormal sleep architecture [<a href="#rid125">125-128</a>]. Sleep disturbance may be related to abnormalities in melatonin, serotonin, or gamma-aminobutyric acid [<a href="#rid129">129,130</a>].</p><p>The evaluation of sleep disturbance in children with ASD should include a thorough sleep history and screen for obstructive apnea and other sleep disorders. Referral to a specialist (eg, sleep specialist, neurologist, otolaryngologist) may be warranted if a specific sleep disorder is identified or suspected. (See  <a class="medical medical_review" href="/d/html/6357.html" rel="external">"Assessment of sleep disorders in children"</a> and  <a class="medical medical_review" href="/d/html/6353.html" rel="external">"Behavioral sleep problems in children"</a> and  <a class="medical medical_review" href="/d/html/6363.html" rel="external">"Evaluation of suspected obstructive sleep apnea in children"</a>.)</p><p>It is important to ensure appropriate sleep hygiene and use behavioral interventions to decrease sleep associations before considering pharmacologic interventions [<a href="#rid131">131-135</a>]. Medications are unlikely to be effective in the absence of an appropriate sleep schedule.</p><p>There is little evidence for pharmacologic management of sleep disturbance in children. No medications are approved by the US Food and Drug Administration (FDA) for use for sleep in ASD. However, several are used in clinical practice.</p><p class="headingAnchor" id="H29"><span class="h3">Melatonin</span><span class="headingEndMark"> — </span>The benefits of melatonin for sleep onset and maintenance in children with ASD have been suggested in observational, open-label studies and randomized placebo-controlled trials [<a href="#rid135">135-147</a>]. In a meta-analysis of five randomized crossover trials (including a total of 57 patients) of melatonin in children with ASD, melatonin increased sleep duration by 73 minutes and decreased sleep onset latency by 66 minutes compared with placebo but did not affect nighttime awakenings [<a href="#rid142">142</a>]. Side effects were minimal. In individual studies, the doses ranged from 0.75 to 10 mg/day, and the duration of treatment ranged from 14 days to 6 months [<a href="#rid139">139,140,143-145,147,148</a>].</p><p>These results suggest that in the short-term (ie, up to six months), 1 to 10 mg of melatonin may be effective in helping children with ASD to fall asleep and sleep longer when provided 30 minutes before bedtime. However, there are no dosing guidelines for administration and no information on long-term use or side effects. Side effects of melatonin may include difficulty waking, daytime sleepiness, and enuresis [<a href="#rid137">137,138</a>].</p><p>We suggest melatonin for patients with ASD who have difficulty falling asleep and staying asleep despite appropriate sleep hygiene and behavioral or environmental interventions. We usually start with 0.5 to 1 mg, depending upon age, and increase by 1 mg as needed to a maximum of 10 mg (although in clinical practice, others may use a higher dose).</p><p>Melatonin is sold over the counter and does not require a prescription. It is not regulated by the FDA. When parents/caregivers purchase melatonin, they should seek a formulation that contains melatonin as the only active ingredient.</p><p class="headingAnchor" id="H30"><span class="h3">Other agents</span><span class="headingEndMark"> — </span>Some data suggest that low serum ferritin levels in children with ASD may contribute to symptoms of restless sleep (even in children with normal iron levels) [<a href="#rid149">149</a>]. In an observational study, oral iron supplementation was beneficial in improving restless sleep in children with ASD and decreased serum ferritin [<a href="#rid149">149</a>].</p><p>Other agents that have been studied in the management of sleep disturbance (increased sleep latency, night wakings, and decreased total sleep) in children with ASD include niaprazine, <a class="drug drug_pediatric" data-topicid="13171" href="/d/drug information/13171.html" rel="external">clonidine</a>, and <a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">risperidone</a> [<a href="#rid17">17</a>]. In addition, for children who require antiseizure or antidepressant medications, the timing of administration can be manipulated to take advantage of the sedative effects.</p><p>There are few data to support the use of these medications for sleep in children with ASD. When used, they should be started at the lowest available dose and titrated as necessary.</p><p class="bulletIndent1"><span class="glyph">●</span>Niaprazine is a histamine H1-receptor antagonist with sedative properties that is available in Europe [<a href="#rid150">150,151</a>]. In an open study in 25 patients with ASD and sleep disorder, niaprazine (1 mg/kg per day for 60 days) was associated with improvement in behavior and sleep disorders; no side effects were observed [<a href="#rid151">151</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13171" href="/d/drug information/13171.html" rel="external">Clonidine</a> (an alpha-2-adrenergic receptor agonist) has sedative effects. In an observational study, clonidine was effective in reducing sleep latency and nighttime awakening in children with ASD [<a href="#rid152">152</a>]. Side effects of clonidine include hypotension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a patient who presents with sleep difficulties also is prescribed a medication with a sedating effect (eg, <a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">risperidone</a>, some antiseizure medications, some antidepressants), the sedating medication could be administered at bedtime; or, if more than one dose is recommended, the higher dose can be administered at bedtime, if appropriate. However, given the potential adverse effects, the use of sedating medications for sleep disturbance alone is not recommended.</p><p></p><p class="headingAnchor" id="H31"><span class="h2">Parasomnias</span><span class="headingEndMark"> — </span>Parasomnias or nonrapid eye movement (NREM) arousal disorders include sleep walking, sleep terrors, and confusional arousals (see  <a class="medical medical_review" href="/d/html/16588.html" rel="external">"Parasomnias of childhood, including sleepwalking", section on 'Disorders of arousal from non-rapid eye movement sleep'</a>). <a class="drug drug_pediatric" data-topicid="13170" href="/d/drug information/13170.html" rel="external">Clonazepam</a> and tricyclic antidepressants have been used to treat NREM arousal disorders in children with ASD [<a href="#rid131">131</a>]. However, high-quality evidence to support their use is lacking.</p><p class="headingAnchor" id="H1400792245"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/121690.html" rel="external">"Society guideline links: Autism spectrum disorder"</a>.)</p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The target symptom(s) for pharmacotherapy in children with autism spectrum disorder (ASD) should be clearly defined. Medical causes for the behavior should be excluded, and behavioral interventions should be maximized before pharmacotherapy is initiated. (See <a class="local">'Pretreatment evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When considering the use of medications for target symptoms, the potential benefits and risks must be weighed on a case-by-case basis. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psychopharmacotherapy for children and adolescents with ASD ideally is prescribed by specialists familiar with ASD (eg, developmental pediatrician, child psychiatrist, child neurologist). Primary care clinicians who undertake the prescription of psychotropic agents for children with ASD should consider consultation with a specialist. (See <a class="local">'Who should prescribe?'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with ASD who are receiving pharmacologic therapy for target symptoms must be monitored regularly for efficacy and side effects. Additional precautions may be necessary for children receiving more than one psychoactive medication. (See <a class="local">'Monitoring'</a> above and <a class="local">'Polypharmacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When, after careful assessment of the patient and a discussion of the potential risks and benefits, the clinician and parents/patient agree that pharmacotherapy is indicated for target symptoms in children with ASD:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For inattention and hyperactivity that are not thought to be related to other symptoms, such as anxiety, we suggest <a class="drug drug_pediatric" data-topicid="12600" href="/d/drug information/12600.html" rel="external">methylphenidate</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Other stimulants, alpha agonists, and <a class="drug drug_pediatric" data-topicid="13048" href="/d/drug information/13048.html" rel="external">atomoxetine</a> also have been used. (See <a class="local">'Approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For maladaptive behaviors including aggression and self-injury that are not thought to be related to other symptoms, we suggest <a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">risperidone</a> or <a class="drug drug_pediatric" data-topicid="13180" href="/d/drug information/13180.html" rel="external">aripiprazole</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_4" rel="external">Grade 2A</a>). Other medications (eg, stimulants, selective serotonin reuptake inhibitors [SSRI], alpha-adrenergic agonists) may be more appropriate, depending upon the underlying cause of aggression (eg, hyperactivity, anxiety, impulsivity). (See <a class="local">'Treatment approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For isolated repetitive behaviors, evidence is lacking to recommend a specific SSRI; however, we suggest <a class="drug drug_pediatric" data-topicid="13315" href="/d/drug information/13315.html" rel="external">fluoxetine</a>, <a class="drug drug_pediatric" data-topicid="12787" href="/d/drug information/12787.html" rel="external">sertraline</a>, or another SSRI as the initial medication for interfering repetitive behavior (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>), especially if the behaviors are exacerbated by anxiety. (See <a class="local">'Repetitive behaviors and rigidity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For anxiety, we suggest an SSRI as the initial medication (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Anxiety'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For dysregulated mood, we suggest an atypical antipsychotic or SSRI as the initial medication (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Mood lability'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For depressive symptoms, we suggest an SSRI or serotonin norepinephrine reuptake inhibitor as the initial medication (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Depression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pharmacologic management of seizures in children with ASD is similar to that of seizures in children without ASD. (See  <a class="medical medical_review" href="/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal disorders in children with ASD generally should be managed in the same way as in children without ASD. (See <a class="local">'Gastrointestinal problems'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Melatonin may be beneficial for sleep disturbance (late onset, frequent waking, restlessness) that persists despite appropriate sleep hygiene and behavioral interventions. (See <a class="local">'Melatonin'</a> above.)</p><p></p><p class="headingAnchor" id="H507725708"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>We are saddened by the death of Carolyn Bridgemohan, MD, who passed away in August 2019. UpToDate wishes to acknowledge Dr. Bridgemohan's many contributions to pediatrics, in particular, her work as our Section Editor for Developmental and Behavioral Pediatrics.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">American Psychiatric Association. Autism spectrum disorder. In: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, American Psychiatric Association, Arlington, VA 2013. p.50.</li><li><a class="nounderline abstract_t">McGuire K, Fung LK, Hagopian L, et al. Irritability and Problem Behavior in Autism Spectrum Disorder: A Practice Pathway for Pediatric Primary Care. Pediatrics 2016; 137 Suppl 2:S136.</a></li><li><a class="nounderline abstract_t">Towbin KE. Strategies for pharmacologic treatment of high functioning autism and Asperger syndrome. Child Adolesc Psychiatr Clin N Am 2003; 12:23.</a></li><li><a class="nounderline abstract_t">Aman MG, Farmer CA, Hollway J, Arnold LE. Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2008; 17:713.</a></li><li><a class="nounderline abstract_t">Aman MG, Novotny S, Samango-Sprouse C, et al. Outcome measures for clinical drug trials in autism. CNS Spectr 2004; 9:36.</a></li><li><a class="nounderline abstract_t">Kaat AJ, Lecavalier L, Aman MG. Validity of the aberrant behavior checklist in children with autism spectrum disorder. J Autism Dev Disord 2014; 44:1103.</a></li><li><a class="nounderline abstract_t">Myers SM. The status of pharmacotherapy for autism spectrum disorders. Expert Opin Pharmacother 2007; 8:1579.</a></li><li class="breakAll">Scottish Intercollegiate Guidelines Network. Assessment, diagnosis and clinical interventions for children and young people with autism spectrum disorders. A national clinical guideline. Scottish Intercollegiate Guidelines Network, Edinburgh 2007. www.sign.ac.uk/guidelines/fulltext/98/index.html (Accessed on November 10, 2011).</li><li><a class="nounderline abstract_t">Hyman SL, Levy SE, Myers SM, COUNCIL ON CHILDREN WITH DISABILITIES, SECTION ON DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS. Identification, Evaluation, and Management of Children With Autism Spectrum Disorder. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Volkmar F, Siegel M, Woodbury-Smith M, et al. Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 2014; 53:237.</a></li><li class="breakAll">Abilify (aripiprazole). US Food &amp; Drug Administration (FDA) approved product information. Revised July 2014. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on July 17, 2014).</li><li><a class="nounderline abstract_t">Leskovec TJ, Rowles BM, Findling RL. Pharmacological treatment options for autism spectrum disorders in children and adolescents. Harv Rev Psychiatry 2008; 16:97.</a></li><li><a class="nounderline abstract_t">West L, Waldrop J, Brunssen S. Pharmacologic treatment for the core deficits and associated symptoms of autism in children. J Pediatr Health Care 2009; 23:75.</a></li><li><a class="nounderline abstract_t">Parikh MS, Kolevzon A, Hollander E. Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. J Child Adolesc Psychopharmacol 2008; 18:157.</a></li><li><a class="nounderline abstract_t">Ching H, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012; :CD009043.</a></li><li><a class="nounderline abstract_t">Oswald DP, Sonenklar NA. Medication use among children with autism spectrum disorders. J Child Adolesc Psychopharmacol 2007; 17:348.</a></li><li><a class="nounderline abstract_t">Huffman LC, Sutcliffe TL, Tanner IS, Feldman HM. Management of symptoms in children with autism spectrum disorders: a comprehensive review of pharmacologic and complementary-alternative medicine treatments. J Dev Behav Pediatr 2011; 32:56.</a></li><li><a class="nounderline abstract_t">Quintana H, Birmaher B, Stedge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 1995; 25:283.</a></li><li><a class="nounderline abstract_t">Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 2000; 30:245.</a></li><li><a class="nounderline abstract_t">Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005; 62:1266.</a></li><li><a class="nounderline abstract_t">Pearson DA, Santos CW, Aman MG, et al. Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. J Child Adolesc Psychopharmacol 2013; 23:337.</a></li><li><a class="nounderline abstract_t">Sturman N, Deckx L, van Driel ML. Methylphenidate for children and adolescents with autism spectrum disorder. Cochrane Database Syst Rev 2017; 11:CD011144.</a></li><li><a class="nounderline abstract_t">Posey DJ, Aman MG, McCracken JT, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry 2007; 61:538.</a></li><li><a class="nounderline abstract_t">Hazell P. Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder. J Paediatr Child Health 2007; 43:19.</a></li><li><a class="nounderline abstract_t">A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999; 56:1073.</a></li><li><a class="nounderline abstract_t">Posey DJ, Puntney JI, Sasher TM, et al. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 2004; 14:233.</a></li><li><a class="nounderline abstract_t">Scahill L, McCracken JT, King BH, et al. Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. Am J Psychiatry 2015; 172:1197.</a></li><li><a class="nounderline abstract_t">Scahill L, Aman MG, McDougle CJ, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006; 16:589.</a></li><li><a class="nounderline abstract_t">Fankhauser MP, Karumanchi VC, German ML, et al. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992; 53:77.</a></li><li><a class="nounderline abstract_t">Jaselskis CA, Cook EH Jr, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 1992; 12:322.</a></li><li><a class="nounderline abstract_t">Ghanizadeh A. Atomoxetine for treating ADHD symptoms in autism: a systematic review. J Atten Disord 2013; 17:635.</a></li><li><a class="nounderline abstract_t">Harfterkamp M, van de Loo-Neus G, Minderaa RB, et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 2012; 51:733.</a></li><li><a class="nounderline abstract_t">Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006; 45:1196.</a></li><li><a class="nounderline abstract_t">Svanborg P, Thernlund G, Gustafsson PA, et al. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents. Eur Child Adolesc Psychiatry 2009; 18:240.</a></li><li><a class="nounderline abstract_t">Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:1119.</a></li><li><a class="nounderline abstract_t">McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347:314.</a></li><li><a class="nounderline abstract_t">Barnard L, Young AH, Pearson J, et al. A systematic review of the use of atypical antipsychotics in autism. J Psychopharmacol 2002; 16:93.</a></li><li><a class="nounderline abstract_t">Hollander E, Dolgoff-Kaspar R, Cartwright C, et al. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry 2001; 62:530.</a></li><li><a class="nounderline abstract_t">Hardan AY, Jou RJ, Handen BL. A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004; 14:426.</a></li><li><a class="nounderline abstract_t">Belsito KM, Law PA, Kirk KS, et al. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2001; 31:175.</a></li><li><a class="nounderline abstract_t">Mahajan R, Bernal MP, Panzer R, et al. Clinical practice pathways for evaluation and medication choice for attention-deficit/hyperactivity disorder symptoms in autism spectrum disorders. Pediatrics 2012; 130 Suppl 2:S125.</a></li><li><a class="nounderline abstract_t">Frazier TW. Friends not foes: combined risperidone and behavior therapy for irritability in autism. J Am Acad Child Adolesc Psychiatry 2012; 51:129.</a></li><li><a class="nounderline abstract_t">Aman MG, McDougle CJ, Scahill L, et al. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2009; 48:1143.</a></li><li><a class="nounderline abstract_t">Fung LK, Mahajan R, Nozzolillo A, et al. Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis. Pediatrics 2016; 137 Suppl 2:S124.</a></li><li><a class="nounderline abstract_t">McVoy M, Findling R. Child and adolescent psychopharmacology update. Psychiatr Clin North Am 2009; 32:111.</a></li><li><a class="nounderline abstract_t">Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114:e634.</a></li><li><a class="nounderline abstract_t">Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 2006; 21:450.</a></li><li><a class="nounderline abstract_t">Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. Cochrane Database Syst Rev 2007; :CD005040.</a></li><li><a class="nounderline abstract_t">Dove D, Warren Z, McPheeters ML, et al. Medications for adolescents and young adults with autism spectrum disorders: a systematic review. Pediatrics 2012; 130:717.</a></li><li class="breakAll">Williamson E, Sathe NA, Andrews JC. Medical therapies for children with autism spectrum disorder--an update. Comparative Effectiveness Review No. 189. Agency for Healthcare Research and Quality, Rockville, MD May 2017. Available at: https://effectivehealthcare.ahrq.gov/topics/asd-medical/research-2017 (Accessed on April 05, 2018).</li><li><a class="nounderline abstract_t">Howes OD, Rogdaki M, Findon JL, et al. Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. J Psychopharmacol 2018; 32:3.</a></li><li><a class="nounderline abstract_t">McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005; 162:1142.</a></li><li><a class="nounderline abstract_t">Levine SZ, Kodesh A, Goldberg Y, et al. Initial severity and efficacy of risperidone in autism: Results from the RUPP trial. Eur Psychiatry 2016; 32:16.</a></li><li><a class="nounderline abstract_t">Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 2005; 162:1361.</a></li><li class="breakAll">Risperdal (risperidone). US Food and Drug Administration (FDA) approved product information. Revised February, 2021. US National Library of Medicine. Available online at: https://dailymed.nlm.nih.gov/dailymed/ (Accessed on September 29, 2021).</li><li class="breakAll">Risperdal. Approval date(s) and history,  letters, labels, reviews for NDA 020272. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=020272 (Accessed on October 27, 2021).</li><li><a class="nounderline abstract_t">Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009; 124:1533.</a></li><li><a class="nounderline abstract_t">Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009; 48:1110.</a></li><li><a class="nounderline abstract_t">Hirsch LE, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2016; :CD009043.</a></li><li><a class="nounderline abstract_t">Findling RL, Mankoski R, Timko K, et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. J Clin Psychiatry 2014; 75:22.</a></li><li class="breakAll">US Food and Drug Administration. FDA drug safety communication: FDA warns about new impulse-control problems associated with mental health drug aripiprozole (Ability, Abilify Maintena, Aristada). http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm498823.htm (Accessed on May 03, 2016).</li><li><a class="nounderline abstract_t">Potenza MN, Holmes JP, Kanes SJ, McDougle CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999; 19:37.</a></li><li><a class="nounderline abstract_t">Malone RP, Cater J, Sheikh RM, et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001; 40:887.</a></li><li><a class="nounderline abstract_t">Kemner C, Willemsen-Swinkels SH, de Jonge M, et al. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 2002; 22:455.</a></li><li><a class="nounderline abstract_t">Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006; 16:541.</a></li><li><a class="nounderline abstract_t">Malone RP, Delaney MA, Hyman SB, Cater JR. Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol 2007; 17:779.</a></li><li><a class="nounderline abstract_t">Chavez B, Chavez-Brown M, Sopko MA Jr, Rey JA. Atypical antipsychotics in children with pervasive developmental disorders. Paediatr Drugs 2007; 9:249.</a></li><li><a class="nounderline abstract_t">Posey DJ, Stigler KA, Erickson CA, McDougle CJ. Antipsychotics in the treatment of autism. J Clin Invest 2008; 118:6.</a></li><li><a class="nounderline abstract_t">Zuddas A, Ledda MG, Fratta A, et al. Clinical effects of clozapine on autistic disorder. Am J Psychiatry 1996; 153:738.</a></li><li><a class="nounderline abstract_t">Campbell M, Anderson LT, Small AM, et al. The effects of haloperidol on learning and behavior in autistic children. J Autism Dev Disord 1982; 12:167.</a></li><li><a class="nounderline abstract_t">Miral S, Gencer O, Inal-Emiroglu FN, et al. Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry 2008; 17:1.</a></li><li><a class="nounderline abstract_t">Campbell M, Armenteros JL, Malone RP, et al. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 1997; 36:835.</a></li><li><a class="nounderline abstract_t">Hellings JA, Weckbaugh M, Nickel EJ, et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005; 15:682.</a></li><li><a class="nounderline abstract_t">Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302:1765.</a></li><li><a class="nounderline abstract_t">Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006; 16:575.</a></li><li><a class="nounderline abstract_t">Almandil NB, Liu Y, Murray ML, et al. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Paediatr Drugs 2013; 15:139.</a></li><li><a class="nounderline abstract_t">Scahill L, Jeon S, Boorin SJ, et al. Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder. J Am Acad Child Adolesc Psychiatry 2016; 55:415.</a></li><li><a class="nounderline abstract_t">Jensen KG, Juul K, Fink-Jensen A, et al. Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. J Am Acad Child Adolesc Psychiatry 2015; 54:25.</a></li><li><a class="nounderline abstract_t">Arnold LE, Vitiello B, McDougle C, et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 2003; 42:1443.</a></li><li><a class="nounderline abstract_t">American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596.</a></li><li class="breakAll">Parr J. Autism. In: Clinical Evidence Handbook, BMJ Publishing Group, London 2008. p.69.</li><li><a class="nounderline abstract_t">Williams K, Brignell A, Randall M, et al. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2013; :CD004677.</a></li><li><a class="nounderline abstract_t">Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev 2008; :CD001765.</a></li><li><a class="nounderline abstract_t">Reddihough DS, Marraffa C, Mouti A, et al. Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial. JAMA 2019; 322:1561.</a></li><li><a class="nounderline abstract_t">Herscu P, Handen BL, Arnold LE, et al. The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder. J Autism Dev Disord 2020; 50:3233.</a></li><li><a class="nounderline abstract_t">Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005; 30:582.</a></li><li><a class="nounderline abstract_t">McDougle CJ, Kresch LE, Posey DJ. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord 2000; 30:427.</a></li><li><a class="nounderline abstract_t">McDougle CJ, Naylor ST, Cohen DJ, et al. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996; 53:1001.</a></li><li><a class="nounderline abstract_t">McDougle CJ, Brodkin ES, Naylor ST, et al. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol 1998; 18:62.</a></li><li><a class="nounderline abstract_t">Hellings JA, Kelley LA, Gabrielli WF, et al. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry 1996; 57:333.</a></li><li><a class="nounderline abstract_t">Davanzo PA, Belin TR, Widawski MH, King BH. Paroxetine treatment of aggression and self-injury in persons with mental retardation. Am J Ment Retard 1998; 102:427.</a></li><li><a class="nounderline abstract_t">King BH, Hollander E, Sikich L, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 2009; 66:583.</a></li><li><a class="nounderline abstract_t">Owley T, Walton L, Salt J, et al. An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2005; 44:343.</a></li><li><a class="nounderline abstract_t">Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group. Arch Gen Psychiatry 1991; 48:730.</a></li><li><a class="nounderline abstract_t">Gordon CT, State RC, Nelson JE, et al. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993; 50:441.</a></li><li><a class="nounderline abstract_t">Remington G, Sloman L, Konstantareas M, et al. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 2001; 21:440.</a></li><li><a class="nounderline abstract_t">Hurwitz R, Blackmore R, Hazell P, et al. Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents. Cochrane Database Syst Rev 2012; :CD008372.</a></li><li><a class="nounderline abstract_t">Hollander E, Soorya L, Wasserman S, et al. Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol 2006; 9:209.</a></li><li><a class="nounderline abstract_t">Chugani DC, Chugani HT, Wiznitzer M, et al. Efficacy of Low-Dose Buspirone for Restricted and Repetitive Behavior in Young Children with Autism Spectrum Disorder: A Randomized Trial. J Pediatr 2016; 170:45.</a></li><li><a class="nounderline abstract_t">Vasa RA, Mazurek MO, Mahajan R, et al. Assessment and Treatment of Anxiety in Youth With Autism Spectrum Disorders. Pediatrics 2016; 137 Suppl 2:S115.</a></li><li><a class="nounderline abstract_t">White SW, Oswald D, Ollendick T, Scahill L. Anxiety in children and adolescents with autism spectrum disorders. Clin Psychol Rev 2009; 29:216.</a></li><li><a class="nounderline abstract_t">Ung D, Selles R, Small BJ, Storch EA. A Systematic Review and Meta-Analysis of Cognitive-Behavioral Therapy for Anxiety in Youth with High-Functioning Autism Spectrum Disorders. Child Psychiatry Hum Dev 2015; 46:533.</a></li><li><a class="nounderline abstract_t">Lickel A, MacLean WE Jr, Blakeley-Smith A, Hepburn S. Assessment of the prerequisite skills for cognitive behavioral therapy in children with and without autism spectrum disorders. J Autism Dev Disord 2012; 42:992.</a></li><li><a class="nounderline abstract_t">Ipser JC, Stein DJ, Hawkridge S, Hoppe L. Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev 2009; :CD005170.</a></li><li><a class="nounderline abstract_t">Posey DJ, Guenin KD, Kohn AE, et al. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol 2001; 11:267.</a></li><li><a class="nounderline abstract_t">Buitelaar JK, van der Gaag RJ, van der Hoeven J. Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study. J Clin Psychiatry 1998; 59:56.</a></li><li><a class="nounderline abstract_t">Posey DJ, Erickson CA, Stigler KA, McDougle CJ. The use of selective serotonin reuptake inhibitors in autism and related disorders. J Child Adolesc Psychopharmacol 2006; 16:181.</a></li><li><a class="nounderline abstract_t">Hollander E, Novotny S, Hanratty M, et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology 2003; 28:193.</a></li><li><a class="nounderline abstract_t">Andari E, Duhamel JR, Zalla T, et al. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci U S A 2010; 107:4389.</a></li><li><a class="nounderline abstract_t">Gordon I, Vander Wyk BC, Bennett RH, et al. Oxytocin enhances brain function in children with autism. Proc Natl Acad Sci U S A 2013; 110:20953.</a></li><li><a class="nounderline abstract_t">Yatawara CJ, Einfeld SL, Hickie IB, et al. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. Mol Psychiatry 2016; 21:1225.</a></li><li><a class="nounderline abstract_t">Quintana DS, Westlye LT, Hope S, et al. Dose-dependent social-cognitive effects of intranasal oxytocin delivered with novel Breath Powered device in adults with autism spectrum disorder: a randomized placebo-controlled double-blind crossover trial. Transl Psychiatry 2017; 7:e1136.</a></li><li><a class="nounderline abstract_t">Parker KJ, Oztan O, Libove RA, et al. Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. Proc Natl Acad Sci U S A 2017; 114:8119.</a></li><li><a class="nounderline abstract_t">Sikich L, Kolevzon A, King BH, et al. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. N Engl J Med 2021; 385:1462.</a></li><li><a class="nounderline abstract_t">Posey DJ, Kem DL, Swiezy NB, et al. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry 2004; 161:2115.</a></li><li><a class="nounderline abstract_t">Danfors T, von Knorring AL, Hartvig P, et al. Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. J Clin Psychopharmacol 2005; 25:485.</a></li><li><a class="nounderline abstract_t">Hardan AY, Handen BL. A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 2002; 12:237.</a></li><li><a class="nounderline abstract_t">Chez MG, Aimonovitch M, Buchanan T, et al. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol 2004; 19:165.</a></li><li><a class="nounderline abstract_t">Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol 2006; 16:621.</a></li><li><a class="nounderline abstract_t">Chez MG, Burton Q, Dowling T, et al. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol 2007; 22:574.</a></li><li><a class="nounderline abstract_t">Erickson CA, Posey DJ, Stigler KA, et al. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl) 2007; 191:141.</a></li><li><a class="nounderline abstract_t">Farmer C, Thurm A, Grant P. Pharmacotherapy for the core symptoms in autistic disorder: current status of the research. Drugs 2013; 73:303.</a></li><li><a class="nounderline abstract_t">McElhanon BO, McCracken C, Karpen S, Sharp WG. Gastrointestinal symptoms in autism spectrum disorder: a meta-analysis. Pediatrics 2014; 133:872.</a></li><li><a class="nounderline abstract_t">Buie T, Fuchs GJ 3rd, Furuta GT, et al. Recommendations for evaluation and treatment of common gastrointestinal problems in children with ASDs. Pediatrics 2010; 125 Suppl 1:S19.</a></li><li><a class="nounderline abstract_t">Elrod MG, Hood BS. Sleep differences among children with autism spectrum disorders and typically developing peers: a meta-analysis. J Dev Behav Pediatr 2015; 36:166.</a></li><li><a class="nounderline abstract_t">Malow BA, Katz T, Reynolds AM, et al. Sleep Difficulties and Medications in Children With Autism Spectrum Disorders: A Registry Study. Pediatrics 2016; 137 Suppl 2:S98.</a></li><li><a class="nounderline abstract_t">Reynolds AM, Soke GN, Sabourin KR, et al. Sleep Problems in 2- to 5-Year-Olds With Autism Spectrum Disorder and Other Developmental Delays. Pediatrics 2019; 143.</a></li><li><a class="nounderline abstract_t">Valicenti-McDermott M, Lawson K, Hottinger K, et al. Sleep Problems in Children With Autism and Other Developmental Disabilities: A Brief Report. J Child Neurol 2019; 34:387.</a></li><li><a class="nounderline abstract_t">Richdale AL, Schreck KA. Sleep problems in autism spectrum disorders: prevalence, nature, &amp; possible biopsychosocial aetiologies. Sleep Med Rev 2009; 13:403.</a></li><li><a class="nounderline abstract_t">Kotagal S, Broomall E. Sleep in children with autism spectrum disorder. Pediatr Neurol 2012; 47:242.</a></li><li><a class="nounderline abstract_t">Johnson KP, Giannotti F, Cortesi F. Sleep patterns in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2009; 18:917.</a></li><li><a class="nounderline abstract_t">Appleton RE, Gringras P. Melatonin: helping to MEND impaired sleep. Arch Dis Child 2013; 98:216.</a></li><li><a class="nounderline abstract_t">Appleton RE, Jones AP, Gamble C, et al. The use of MElatonin in children with neurodevelopmental disorders and impaired sleep: a randomised, double-blind, placebo-controlled, parallel study (MENDS). Health Technol Assess 2012; 16:i.</a></li><li><a class="nounderline abstract_t">Cuomo BM, Vaz S, Lee EAL, et al. Effectiveness of Sleep-Based Interventions for Children with Autism Spectrum Disorder: A Meta-Synthesis. Pharmacotherapy 2017; 37:555.</a></li><li><a class="nounderline abstract_t">Williams Buckley A, Hirtz D, Oskoui M, et al. Practice guideline: Treatment for insomnia and disrupted sleep behavior in children and adolescents with autism spectrum disorder: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2020; 94:392.</a></li><li><a class="nounderline abstract_t">Andersen IM, Kaczmarska J, McGrew SG, Malow BA. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol 2008; 23:482.</a></li><li><a class="nounderline abstract_t">Paavonen EJ, Nieminen-von Wendt T, Vanhala R, et al. Effectiveness of melatonin in the treatment of sleep disturbances in children with Asperger disorder. J Child Adolesc Psychopharmacol 2003; 13:83.</a></li><li><a class="nounderline abstract_t">Giannotti F, Cortesi F, Cerquiglini A, Bernabei P. An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord 2006; 36:741.</a></li><li><a class="nounderline abstract_t">Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 2006; 32:585.</a></li><li><a class="nounderline abstract_t">Wright B, Sims D, Smart S, et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. J Autism Dev Disord 2011; 41:175.</a></li><li><a class="nounderline abstract_t">Guénolé F, Godbout R, Nicolas A, et al. Melatonin for disordered sleep in individuals with autism spectrum disorders: systematic review and discussion. Sleep Med Rev 2011; 15:379.</a></li><li><a class="nounderline abstract_t">Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011; 53:783.</a></li><li><a class="nounderline abstract_t">Wirojanan J, Jacquemont S, Diaz R, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med 2009; 5:145.</a></li><li><a class="nounderline abstract_t">Wasdell MB, Jan JE, Bomben MM, et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res 2008; 44:57.</a></li><li><a class="nounderline abstract_t">McArthur AJ, Budden SS. Sleep dysfunction in Rett syndrome: a trial of exogenous melatonin treatment. Dev Med Child Neurol 1998; 40:186.</a></li><li><a class="nounderline abstract_t">Gringras P, Nir T, Breddy J, et al. Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder. J Am Acad Child Adolesc Psychiatry 2017; 56:948.</a></li><li><a class="nounderline abstract_t">Malow B, Adkins KW, McGrew SG, et al. Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord 2012; 42:1729.</a></li><li><a class="nounderline abstract_t">Goldman SE, Adkins KW, Calcutt MW, et al. Melatonin in children with autism spectrum disorders: endogenous and pharmacokinetic profiles in relation to sleep. J Autism Dev Disord 2014; 44:2525.</a></li><li><a class="nounderline abstract_t">Dosman CF, Brian JA, Drmic IE, et al. Children with autism: effect of iron supplementation on sleep and ferritin. Pediatr Neurol 2007; 36:152.</a></li><li><a class="nounderline abstract_t">Johnson KP, Malow BA. Assessment and pharmacologic treatment of sleep disturbance in autism. Child Adolesc Psychiatr Clin N Am 2008; 17:773.</a></li><li><a class="nounderline abstract_t">Rossi PG, Posar A, Parmeggiani A, et al. Niaprazine in the treatment of autistic disorder. J Child Neurol 1999; 14:547.</a></li><li><a class="nounderline abstract_t">Ming X, Gordon E, Kang N, Wagner GC. Use of clonidine in children with autism spectrum disorders. Brain Dev 2008; 30:454.</a></li></ol></div><div id="topicVersionRevision">Topic 603 Version 55.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : American Psychiatric Association. Autism spectrum disorder. In: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, American Psychiatric Association, Arlington, VA 2013. p.50.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26908469" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Irritability and Problem Behavior in Autism Spectrum Disorder: A Practice Pathway for Pediatric Primary Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12512397" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Strategies for pharmacologic treatment of high functioning autism and Asperger syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18775366" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999174" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Outcome measures for clinical drug trials in autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24165702" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Validity of the aberrant behavior checklist in children with autism spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17685878" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The status of pharmacotherapy for autism spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17685878" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The status of pharmacotherapy for autism spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31843864" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Identification, Evaluation, and Management of Children With Autism Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24472258" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24472258" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18415882" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pharmacological treatment options for autism spectrum disorders in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19232924" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pharmacologic treatment for the core deficits and associated symptoms of autism in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18439113" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22592735" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Aripiprazole for autism spectrum disorders (ASD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17630868" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Medication use among children with autism spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21160435" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Management of symptoms in children with autism spectrum disorders: a comprehensive review of pharmacologic and complementary-alternative medicine treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7559293" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Use of methylphenidate in the treatment of children with autistic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11055460" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16275814" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23782128" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29159857" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Methylphenidate for children and adolescents with autism spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17276750" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17207050" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10591283" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15319020" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26315981" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17069547" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A prospective open trial of guanfacine in children with pervasive developmental disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1548248" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1479049" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clonidine treatment of hyperactive and impulsive children with autistic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22544388" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Atomoxetine for treating ADHD symptoms in autism: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22721596" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17003665" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19156355" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17712235" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12151468" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Risperidone in children with autism and serious behavioral problems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11949778" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A systematic review of the use of atypical antipsychotics in autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11488363" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : An open trial of divalproex sodium in autism spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15650499" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11450816" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23118243" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical practice pathways for evaluation and medication choice for attention-deficit/hyperactivity disorder symptoms in autism spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22265357" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Friends not foes: combined risperidone and behavior therapy for irritability in autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19858761" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26908468" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19248920" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Child and adolescent psychopharmacology update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15492353" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16948927" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Risperidone in children with autism: randomized, placebo-controlled, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17253538" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Risperidone for autism spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23008452" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Medications for adolescents and young adults with autism spectrum disorders: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23008452" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Medications for adolescents and young adults with autism spectrum disorders: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29237331" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15930063" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26802979" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Initial severity and efficacy of risperidone in autism: Results from the RUPP trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15994720" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15994720" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15994720" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19948625" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19797985" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27344135" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Aripiprazole for autism spectrum disorders (ASD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24502859" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24502859" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9934941" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11501687" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12352267" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Open-label study of olanzapine in children with pervasive developmental disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17069543" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18315450" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Ziprasidone in adolescents with autism: an open-label pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17705564" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Atypical antipsychotics in children with pervasive developmental disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18172517" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Antipsychotics in the treatment of autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8615435" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Clinical effects of clozapine on autistic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7174605" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The effects of haloperidol on learning and behavior in autistic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18080171" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9183140" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16190799" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19861668" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17069546" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23519708" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27126856" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25524787" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14627879" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747245" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Consensus development conference on antipsychotic drugs and obesity and diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747245" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Consensus development conference on antipsychotic drugs and obesity and diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23959778" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18253995" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31638682" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31267292" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15602505" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11098879" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8911223" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9472844" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8778118" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Sertraline response in adults with mental retardation and autistic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9544340" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Paroxetine treatment of aggression and self-injury in persons with mental retardation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19487623" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15782081" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : An open-label trial of escitalopram in pervasive developmental disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1883256" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8498878" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11476129" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22419332" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16316486" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26746121" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Efficacy of Low-Dose Buspirone for Restricted and Repetitive Behavior in Young Children with Autism Spectrum Disorder: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26908467" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Assessment and Treatment of Anxiety in Youth With Autism Spectrum Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19223098" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Anxiety in children and adolescents with autism spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25246292" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : A Systematic Review and Meta-Analysis of Cognitive-Behavioral Therapy for Anxiety in Youth with High-Functioning Autism Spectrum Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21818677" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Assessment of the prerequisite skills for cognitive behavioral therapy in children with and without autism spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19588367" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Pharmacotherapy for anxiety disorders in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11642476" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9501886" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16553538" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : The use of selective serotonin reuptake inhibitors in autism and related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12496956" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20160081" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Promoting social behavior with oxytocin in high-functioning autism spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24297883" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Oxytocin enhances brain function in children with autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26503762" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28534875" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Dose-dependent social-cognitive effects of intranasal oxytocin delivered with novel Breath Powered device in adults with autism spectrum disorder: a randomized placebo-controlled double-blind crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28696286" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34644471" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15514414" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : A pilot study of D-cycloserine in subjects with autistic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16160627" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12427297" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15119476" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17069550" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : A prospective, open-label trial of galantamine in autistic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17690064" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17016714" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : A retrospective study of memantine in children and adolescents with pervasive developmental disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23504356" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Pharmacotherapy for the core symptoms in autistic disorder: current status of the research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24777214" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Gastrointestinal symptoms in autism spectrum disorder: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20048084" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Recommendations for evaluation and treatment of common gastrointestinal problems in children with ASDs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25741949" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Sleep differences among children with autism spectrum disorders and typically developing peers: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26908483" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Sleep Difficulties and Medications in Children With Autism Spectrum Disorders: A Registry Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30745433" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Sleep Problems in 2- to 5-Year-Olds With Autism Spectrum Disorder and Other Developmental Delays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30880542" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Sleep Problems in Children With Autism and Other Developmental Disabilities: A Brief Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19398354" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Sleep problems in autism spectrum disorders: prevalence, nature,&amp;possible biopsychosocial aetiologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22964437" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Sleep in children with autism spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19836696" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Sleep patterns in autism spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23413423" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Melatonin: helping to MEND impaired sleep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23098680" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : The use of MElatonin in children with neurodevelopmental disorders and impaired sleep: a randomised, double-blind, placebo-controlled, parallel study (MENDS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28258648" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Effectiveness of Sleep-Based Interventions for Children with Autism Spectrum Disorder: A Meta-Synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32051244" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Practice guideline: Treatment for insomnia and disrupted sleep behavior in children and adolescents with autism spectrum disorder: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18182647" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Melatonin for insomnia in children with autism spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12804129" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Effectiveness of melatonin in the treatment of sleep disturbances in children with Asperger disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16897403" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16919138" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20535539" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21393033" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Melatonin for disordered sleep in individuals with autism spectrum disorders: systematic review and discussion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21518346" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Melatonin in autism spectrum disorders: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19968048" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18078449" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9566656" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Sleep dysfunction in Rett syndrome: a trial of exogenous melatonin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29096777" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22160300" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24752680" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Melatonin in children with autism spectrum disorders: endogenous and pharmacokinetic profiles in relation to sleep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17352947" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Children with autism: effect of iron supplementation on sleep and ferritin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18775369" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Assessment and pharmacologic treatment of sleep disturbance in autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10456769" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Niaprazine in the treatment of autistic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18280681" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Use of clonidine in children with autism spectrum disorders.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
